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ABSTRACT 
Gene therapy has emerged as a promising precision nano-medicine strategy in the 
treatment of numerous diseases including cancer. At the forefront of its utility are the applications 
of short-interfering RNA (siRNA), that silence oncogenic mRNA expression leading to cancer cell 
death through the RNA interference (RNAi) pathway. Despite the therapeutic potential, siRNAs 
are limited by poor pharmacological properties, which has hindered their translation into the clinic. 
Recent studies, however, have highlighted the applications of modified siRNAs, including the use 
of fluorescent probes and siRNA nanostructures in cancer detection and treatment. The siRNAs 
reported in this thesis are designed to target and silence the overexpression of the Glucose 
Regulated Proteins (GRPs) in cancer. The GRPs are a class of chaperone proteins involved in 
protein folding events within the endoplasmic reticulum. Under physiological or pathological 
stress, some GRPs translocate to the cell surface where they function as signaling receptors for 
oncogenic activity. Therefore, cancer cell surface GRPs have been classified as clinically proven 
biomarkers.  
Chapter 2 outlines the design, synthesis and characterization of linear as well as novel V- 
and Y-shape RNA templates with the use of a ribouridine branchpoint synthon. The RNA 
templates self-assembled into spheres, triangles, squares, pentagons and hexagons of discrete sizes 
and shapes, confirmed by native PAGE while TEM imaging validated the sizes and shapes of the 
siRNA nanostructures. Moreover, thermal denaturation and CD spectroscopy were used to 
ascertain the prerequisite siRNA hybrids for their RNAi applications. Of interest from this initial 
study, the self-assembled siRNA hybrids (5 nM) that targeted GRP-75, 78 and 95 elicited a 
synergistic effect, which resulted in potent gene knockdown as well as cancer cell death.   
vi 
 
The simultaneous integration of therapy and diagnostics (“theranostics”) has been utilized 
to diagnose and treat cancers at their earliest stages, when they are most likely curable or at least 
treatable. Building on the work described in Chapter 2, the covalently attachment of fluorescein 
isothiocyanate (FITC) allowed for monitoring cell uptake and biological activity of a wide range 
of siRNA motifs. Incorporation of FITC had negligible influence on the A-type helix of the 
siRNAs, while maintaining good hybrid thermal stability. The FL-siRNAs showed some degree 
of fluorescence quenching relative to the unlabeled siRNAs. However, the higher-order V- and Y-
shape siRNA structures enabled the incorporation of multiple fluorescent reporters, which 
increased siRNA fluorescence but failed to overcome the quenching effects. Upon transfection 
within the PC-3 prostate cancer cells, the FL-siRNA hybrids (50 nM) exhibited less mRNA 
knockdown (~10-30%) when compared to their non-labeled counterparts (~40-80%). Conjugation 
of the FITC probe to the sense strand of the siRNAs re-established mRNA knockdown (~50-
<90%) efficiency which also translated to more potent cancer cell death over a 72 hr period (~20-
95%). Time dependent flow cytometry and fluorescence microscopy revealed the sustained 
presence (up to 72 hr) of FITC within the PC-3 cells, thereby validating siRNA uptake for RNAi 
activity. Of significance, the multi-FITC labeled Y-branch siRNA targeting multiple GRPs 
demonstrated the most potent FITC-signaling and GRP mRNA knockdown, which potentiated 
cancer cell death. Taken together, this thesis will serve to highlight the synthesis, characterization 
and biological evaluation of a new class of theranostic siRNA molecular beacons for gene therapy 
applications in cancer. 
KEYWORDS: siRNA nanostructures, Theranostics, Cancer gene therapy, Glucose Regulated 
Proteins (GRPs), FITC, Fluorescence, Prostate cancer 
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CHAPTER 1: GENERAL INTRODUCTION INTO THE SELF-ASSEMBLY AND 
BIOLOGICAL FUNCTION OF SIRNAS IN CANCER DETECTION AND THERAPY  
1.1 SIRNA STRUCTURE AND FUNCTION IN THE RNAI PATHWAY 
Ribonucleic acid (RNA) is a biomacromolecule that is essential in various biological roles 
such as coding, regulation, and expression of genes. Similar to DNA, RNA consists of a long 
polynucleotide chain composed of nucleotide building blocks linked via phosphodiester bonds. 
Unlike DNA, RNA is more often found in nature as a single-stranded biological polymer with a 
high tendency to fold onto itself (self-fold), forming a wide range of RNA secondary structures, 
including hairpins, loops, junctions and double-stranded hybrid motifs that are self-assembled via 
intramolecular hydrogen bonding. DNA and RNA are also distinguished by variances within their 
structures (Figure 1.1), which includes: 1) RNA and DNA contain adenine, cytosine and guanine 
bases, but thymine is found in DNA and uracil in RNA. 2) RNA contains a 2’ hydroxyl on the 
sugar backbone while DNA does not. These hydroxyl groups make RNA less stable than DNA 
because it is more prone to hydrolysis, which leads to isomerization and cleavage of the 3’-5’-
phosphodiester bonds. Due to this innate difference in stability, DNA was selected for the function 
of the storage and transmission of genetic information in cells. Studies on the origin of life have 
shown that DNA and RNA might have evolved from nucleic acid building blocks, which may have 
self-assembled into structures that represents RNA as the starting point of the “RNA World” 
hypothesis.1-3  In this model, RNA was found to be the original scaffold for storing and expressing 
genetic information into the evolution of life on earth.2  Most ‘RNA World’ hypotheses include 
three basic assumptions: (1) genetic continuity was assured by the replication of RNA; (2) Watson-
Crick base pairing is the key to replication; and (3) genetically encoded proteins were not involved 
as catalysts.2 
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Figure 1.1 Structural comparison of thymidine, (A), and ribouridine, (B), differences circled in 
blue. Drawn in ChemDraw. 
 
RNAs have played a pivotal role in the central dogma of molecular biology.4,5  In general, 
cellular organisms use messenger RNA (mRNA) to transfer genetic information that is transcribed 
from DNA and translated into functional proteins. Importantly, the primary transcript of mRNA, 
called pre-mRNA, undergoes a series of post-transcriptional modifications, including capping of 
the 5’end with a 7-methylguanine nucleotide diphosphate, the incorporation of a polyadenylate tail 
at the 3’end and numerous splicing reactions, which remove the non-coding sequences, introns, 
and splice together the coding regions, exons. RNAs that are used for purposes other than protein 
synthesis are called as noncoding RNAs (ncRNAs); numerous ncRNAs are responsible for the 
regulation of gene expression.6,7  In prokaryotic cells, small antisense RNAs (asRNAs) regulate 
gene expression by binding and inhibiting the expression of the target mRNA. In eukaryotic cells, 
many small ncRNAs exert inhibitory properties as well; among those, microRNAs (miRNAs)8 and 
small interfering RNA (siRNAs)9,10 are the most studied.  
A       B 
1.1 1.2 
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siRNAs are a class of double-stranded RNA (dsRNA) molecules, 20-25 base pairs in 
length, that operate within the RNA interference (RNAi) pathway, similar to miRNAs.11  In this 
pathway, the siRNAs exhibit their inhibitory activity by silencing mRNA expression.12 siRNAs 
can be naturally obtained by enzymatic processing of long dsRNAs by the Dicer enzyme.13  These 
siRNA fragments have a well-defined structure, consisting of phosphorylated 5’ends 
and hydroxylated 3’ends containing two overhanging nucleotides (Figure 1.2).14,15 
 
Figure 1.2 Differences between miRNA and siRNA. Reprinted with permission from Springer 
Nature: Mack, G.S. Nature Biotechnol. 2007, 25 (6), 631–638.16 
 
In the RNAi pathway, siRNAs are transfected into the cytoplasm of the cell with the use 
of a transfection reagent. A transfection reagent is a cationic polymer that can effectively condense 
and facilitate siRNA cell permeability.17,18 The siRNAs are released, via endosomal escape, and 
recruited into the RNA-Induced Silencing Complex (RISC). (Figure 1.3) The Argonaute (Ago2), 
protein which features a RNAse III type domain, selects the antisense strand (guide strand),19,20 
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and degrades the sense strand (non-guide strand) of the siRNA hybrid.21 The antisense strand 
serves as a template for mRNA recognition and binds to the complementary mRNA sequence. 
Cleavage sites for sense strand are located near the central region of the siRNA duplex. The 5′ end, 
and not the 3′ end, of the guide siRNA strand sets the position of mRNA cleavage.22,23 Degradation 
of mRNA prevents protein translation which may compromise cell-based function and cell 
viability. The latter can be applied in gene therapy strategies to effectively silence unwanted gene 
products and alter cell-based function.12 The RNAi mechanism for silencing gene expression has 
received substantial attention since the pioneering work of Fire and Mello produced a full 
understanding of the RNAi pathway in Caenorhabditis elegans in 1998,24  from which they were 
later awarded the Nobel Prize in 2006. Upon discovery, others quickly reported that synthetic 
siRNAs, introduced into cells by transfection, could induce RNAi in mammalian cells.9  Since in 
principle any gene25 can be knocked down by synthetic siRNA through the RNAi pathway, it has 
become evident that this treatment strategy has immense potential in suppression of diseased gene 
targets. Thus, the RNAi strategy has been developed into a precise, efficient, stable and more 
potent technology for gene suppression when compared to pre-existing (i.e. antisense or antigene) 
strategies.26 
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Figure 1.3 Schematic representation of siRNA mediated gene silencing via RNAi mechanism. 
Adapted with permission from Elsevier: Schwarz, D.S.; Hutvágner, G.; Haley, B.; Zamore, P.D. 
Molecular Cell. 2002, 10 (3), 537-548.119  
 
1.2 SIRNA APPLICATIONS IN CANCER GENE THERAPY 
The ability for siRNAs to silence target genes with high efficiency and specificity has 
stimulated efforts to develop these molecules into therapeutic agents. Oncogenes, mutated tumor 
suppressor genes and others involved in tumor progression are viable oncogene targets for 
silencing by the RNAi-based therapy approach. This important precision medicine strategy 
contains the capabilities of effectively targeting and inhibiting the expression of oncogenes with 
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high affinity and specificity when compared to non-specific chemo- or radio-therapies or invasive 
surgical procedures. RNAi-based therapy is especially compelling with difficult or undruggable 
oncoprotein targets that may be effectively suppressed by silencing their oncogene expression 
upstream.27 The major advantage of RNAi in cancer therapy is the ability to target multiple genes 
in the various cellular pathways involved in tumor progression.28 This RNAi screening strategy 
has been applied for the validation of important oncogene targets (Table 1.1). 
Pathway Target gene   Pathway Target gene 
Apoptosis 
  
Bax29 
Bcl-230, 31 
  Signaling 
  
  
  
  
  
H-Ras,30 K-Ras37 
PLK-138 
TGF-β30 
STAT339 
EGFR40,41 
PKC-α30 
Angiogenesis Focal adhesion 
kinase (FAK)232 
Adhesion Matrix 
metalloproteinase33 
Cell–cell 
communication 
VEGF30,34 
Lipid metabolism Fatty acid 
synthase35 
Transport MDR36 Viral, oncogenes, nuclear 
  
  
  
LMP-142 
HPV E643 
BCR-Abl44,45 
Telomerase46 
 
Table 1.1 Cancer-associated genes targeted by siRNAs. Adapted from: Devi, G.R. Cancer Gene 
Therapy. 2006, 13 (9), 819-26.47 
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Although siRNAs are promising candidates for cancer gene therapy, there are several 
challenges that must be overcome to help translate the application of siRNAs from pre-clinical to 
clinical utility. For example, un-modified (native) siRNAs are readily degraded within the cellular 
environment by nucleases they exhibit poor uptake and low resident time at desired cellular target 
sites which results in limited potency as well as a relatively high propensity of off-target side-
effects.48 The pursuit of clinically viable antisense drugs has led to the development of various 
strategies that can overcome these problems. Various carriers of siRNA have been developed to 
increase siRNA stability and loading efficacy within RNAi which, in turn leads to long-term 
knockdown of targeted genes.27,49 Carriers typically involve a positively charged vector (e.g., 
cationic cell-penetrating peptides, cationic polymers and lipids), lipid and polymer-based systems 
for encapsulating and releasing the siRNA at the target sites.27,50 Despite the challenges, the 
effectiveness of siRNA therapies has been extensively demonstrated in preclinical studies, and 
some have already entered clinical trials for the treatment of cancer and several other diseases.51,52 
(Table 1.2)  Therapeutic siRNAs can be designed to target various  biological targets (markers) in 
cancer, including those related to: (1) cell-cycle: polo-like kinase 1 (PLK1),53 kinesin spindle 
protein (KSP),54 and ribonucleotide reductase M2 subunit (RRM2);55 (2) signaling: 
KRAS(G12D);56 (3) proliferation: protein kinase N3 (PKN3)57,58 and tenascin C;59 and (4) 
angiogenesis: vascular endothelial growth factor (VEGF).30,34  
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Therapeutic siRNAs Target Pharmaceutical Company 
ALN-RSV01 RSV nucleocapsid Alnylam Pharmaceuticals 
ALN-TTR02 transthyretin (TTR) Alnylam Pharmaceuticals 
PF-04523655 (formerly 
known as RTP-801i) 
HIF-1-responsive gene, 
RTP801 
Quark Pharmaceuticals 
QPI-1002 p53 Quark Pharmaceuticals 
Excellair spleen tyrosine kinase (SYK) 
gene 
Zabecor Pharmaceuticals 
ALN-VSP VEGF gene, kinesin spindle 
(KSP) protein gene 
Alnylam Pharmaceuticals 
CALAA-01 M2 subunit of ribonucleotide 
reductase (RRM2) gene 
Calando Pharmaceuticals 
Atu-027 protein kinase N3 gene Silence Therapeutics 
PF-655 (formerly 
REDD14NP and RTP801i) 
RTP801 gene Quark Pharm 
QPI-1007 caspase-2 gene Quark Pharm 
AGN211745 VEGF-R1 gene Sirna Therapeutics 
ApoB SNALP apolipoprotein B gene Tekmira Pharmaceuticals 
RXI-109 connective tissue growth 
factor (CTGF) gene 
RXi Pharmaceuticals 
SYL040012 β2-adrenergic receptor gene Sirna Therapeutics 
Bevasiranib VEGF gene OPKO Health 
AGN21174 VEGF-R1 gene Allergan 
SPC2996 Bcl-2 gene Santaris Pharma 
 
Table 1.2 Therapeutic siRNAs in clinical development. Adapted from: Chakraborty, C.; Sharma, 
A. R.; Sharma, G.; Doss, C.G.P.; Lee, S. Molecular Therapy. Nucleic Acids. 2017, 8, 132–143.60 
 
1.3 METHODS AND APPLICATIONS OF SIRNA SELF-ASSEMBLY AND NON-COVALENT 
CONJUGATION FOR THERAPEUTICS 
Most biologically active RNAs, including mRNA, transfer RNA (tRNA), ribosomal 
RNA (rRNA) and other ncRNAs contain self-complementary sequences which templates RNA 
folding61 and self-pairing to form double-stranded RNA (dsRNA) helices as well as other 
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secondary structures. The unique ability for RNA to self-assemble as well as interact with other 
biological molecules makes RNA a promising tool for a variety of applications in nanomedicine 
and synthetic biology.62-66 There are two main RNA self-assembly strategies; template and non-
template self-assembly. Template assembly involves the interaction of RNA molecules under the 
influence of specific external sequences, forces, or spatial constraints which helps pre-organize 
intermolecular RNA folding interactions. In contrast, non-template assembly involves the 
formation of larger structures by individual components without the influence of external forces 
and is a contributing factor in RNA self-folding. Single-stranded RNA (ssRNA) assembly is one 
of at least four distinct types of RNA self-assembly strategies.67 ssRNA assembly relies on 
complementary RNA that self-assemble through kinetic and thermodynamically driven Watson-
Crick base pairing or hydrogen-bonding interactions. The ability of RNA to produce kinetically 
controlled self-assemblies using the endogenous transcription machinery has gained widespread 
attraction in the formation of bio-synthetic RNA nanostructures in-vitro or in-vivo.68-71 
The application of functional, self-assembled RNAs is contingent on efficient and 
biocompatible cell delivery methods. There are two broad strategies for RNA delivery into cells, 
tissues and live organisms. RNA can be condensed into an ionic complex to form a nanocarrier or 
RNA can be directly chemically modified, most commonly with a targeting ligand, while 
preserving the molecular nature of the conjugate that is amenable to RNA intracellular delivery 
(Figure 1.4). A fundamental difference between the two approaches lies in the size of the delivery 
moiety, nanoscale versus macro scale, which has profound effects on the biological distribution 
and actions of the transfected RNA. A commonly used delivery approach in pre-clinical and 
clinical applications is related to the formation of ionic complexes in between the negatively 
charged RNAs with the cationic lipids, thus forming lipid nanoparticles (LNPs).72-74 LNPs are 
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especially useful for therapeutic siRNAs75 delivery and have been successfully applied in clinical 
trials.76 While LNPs are effective as cell culture siRNA transfection agents, their use in vivo is 
limited. Another common approach involves the direct complexation of RNA with cationic 
molecules that have some degree of endosomal escape capability that is inherent in their chemistry. 
This would include formation of nanoscale polyplexes involving cell penetrating peptides 
(CPPs),77,78 cationic dendrimers such as PAMAMs79,80 or linear or cross-linked poly ethyleneimine 
(PEI).81 CPPs have been extensively studied in siRNA delivery applications due to their inherent 
abilities to form stable ionic complexes that can efficiently penetrate the cell membrane and release 
the siRNAs intracellularly for RNAi activity.82-83 Moreover, CPPs are biocompatible and exhibit 
minimal toxicity or immunostimulatory effects. Cancer targeting peptides (CTPs) are also utilized 
in siRNA delivery. These peptides are designed to target specific receptors located at the cell 
surface, which allows for targeted delivery of siRNA. CTPs have been conjugated with siRNAs84-
86 while CPPs are formulated into stable ionic complexes for RNAi application.87,88 These are 
usually in the 100–200 nm range with a surface charge density that depends on the chemistry of 
the CPP and the ratio of cationic peptide to siRNA.  
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Figure 1.4: Oligonucleotide delivery strategies. (A) Antibody-oligonucleotide conjugate. (B) 
Polymer-oligonucleotide conjugate with PEGylation and targeting ligand. (C) Molecular scale 
ligand-oligonucleotide conjugate with triantennary carbohydrate ligand. (D) Lipid nanoparticle 
with PEGylation. (E) Gold nanoparticle with dense oligonucleotide coat. (F) DNA nanostructure 
with oligonucleotide and targeting ligand incorporated. Reprinted with permission from Oxford 
University Press: Juliano, R.L. Nucleic Acids Research. 2016, 44 (14), 6518–48.89 
 
1.4 COVALENT BIOCONJUGATION STRATEGIES WITH SIRNA  
Covalent modifications of siRNAs have also been developed to help improve cell 
permeability and RNAi activity. siRNA modifications have been introduced at the 5’ and 3’ 
termini as well sequence modifiers which introduces chemically modified RNA during solid phase 
synthesis. Solid phase synthesis of RNA bioconjugates provides the ability to effectively 
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synthesize the desired bioconjugate on solid support. Solid phase conjugation allows the use of 
excess reagents to push the reaction towards completion. Upon completion, excess reagents are 
simply washed away leaving behind the desired bioconjugate to be subsequently cleaved from the 
solid support and purified. In certain cases, however, solution phase conjugation is the method of 
choice particularly when the conjugate moiety is unstable under typical ammonia cleavage 
conditions.90-92 Several types of reversible and irreversible linkages have been exploited in siRNA 
conjugation chemistry. Bio-orthogonal conjugation approaches have received special attention in 
this area. These post-synthetic conjugation methods can be efficiently utilized in both solid 
supported and solution phase synthesis.  
A common modification in siRNA conjugation chemistry consists of a reactive primary 
amine which forms an irreversible amide bond when reacted with an activated carboxyl group,93 
or a thiourea linkage upon reaction with an isothiocyanate.94 Another valuable conjugation strategy 
involves the use of sulfur containing linkages such as disulfides.95 Disulfides are interesting 
linkages due to their reversible nature under redox conditions. The cytosol within the cellular 
environment is typically a reducing environment, which allows the disulfide-linked siRNAs to be 
liberated for RNAi activity. Synthesis of disulfide linkages can be obtained by reaction of free 
thiol group with an adjacent reactive thiol. The use of “click-chemistry”, also known as Huisgen 
1,3-dipolar cycloaddition, has also been developed for functionalizing oligonucleotides.96 The 
click reaction usually works with high efficiency and involves a Cu(I)-catalyzed azide-alkyne 
cycloaddition (CuAAC), forming a stable triazole linkage in aqueous solvents at room 
temperature. This reaction, however, requires the removal of the copper catalyst from the reaction 
mixture which may be cytotoxic in biological assays. Alternatively, copper-free click reactions 
have recently been developed by using strained cyclooctyne derivatives, which reacts with an azide 
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moiety very efficiently, without any catalyst and the reaction can be performed in aqueous 
medium.97,98 A wide range of chemically reversible and irreversible covalent linkages have been 
developed to functionalize siRNAs with new reporter groups and bio-active probes that have 
served to improve the biological activity of siRNAs in live cells and in vivo applications (Figure 
1.5).  
 
Figure 1.5 Examples of solution and solid-phase oligonucleotide bioconjugation strategies. Drawn 
in ChemDraw. For more examples see: Singh, Y.; Murat, P.; Defrancq, E. Chem. Soc. Rev. 2010, 
39, 2054-2070.91 
 
1.5 APPLICATION OF FLUORESCENT SIRNAS IN LIVE CELL IMAGING AND GENE THERAPY 
SiRNA bioconjugates have been extensively applied as theranostic (therapeutic and 
diagnostic) agents in oncology in order to specifically detect and treat the malignant tumor at the 
localized site in a preventative precision medicine strategy. Moreover, the introduction of 
fluorescent probes represents an important development in siRNA conjugation and are widely used 
in real time PCR, flow cytometry, intracellular localization and detection of molecular 
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interactions.99,100 Labeling of the siRNAs with a fluorescent reporter is typically achieved at either 
the 3’ or 5’ terminus but labeling can also be achieved on nucleobases (mainly at the C-5 position 
of pyrimidines) as well as on the sugar backbone.101 To date, a large number of ﬂuorescence probes 
have been designed for labeling the biomolecules and investigating their structure, biophysical and 
biological properties.102 A common fluorescent probe(s) used for imaging within the cellular 
environment are the cyanine family of dyes.  
Cyanine dyes (Cy3, 1.7, and Cy5, 1.8) are composed of two indole rings and three or five 
methine (CH) groups (Figure 1.6). Its advantages include sharp absorption bands, high extinction 
coefficients, great photo-stability and low pH sensitivity.103 These cyanine dyes also have unique 
properties when conjugated within the same siRNA; they can function as fluorescence resonance 
energy transfer (FRET) probes. A siRNA-based molecular beacon was developed for the detection 
and knockdown of telomerase expression in human breast cancer cells.104 The molecular beacon, 
containing the FRET pair (Cy3/ Cy5), was activated upon binding to the telomerase messenger 
RNA in cells. Aside from reported gene-silencing (~80%), the activation of the molecular beacon 
in cancer cells facilitated visualization of live cell images that were collected by with fluorescence 
microscopy. Although the Cy3 and Cy5 dyes have been used siRNA applications, their 
incorporation have been mostly limited to the sense strand. It has been assumed that modifications 
at the 5’ terminus of the antisense strand negatively influences RISC incorporation of the siRNA 
bioconjugates.105 This is partly due to the requirement of a 5′ phosphate for siRNA incorporation 
into RISC. To test whether the introduction of a fluorescent probe on the antisense strand would 
have an adverse effect on siRNA silencing, siRNA that was either unlabeled, labeled with Cy3 
alone (on the antisense stand), or doubly labeled with Cy3 on the antisense strand and FAM on the 
sense strand was administered to immortalized human pancreatic endocrine cell lines targeting the 
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3' untranslated region (UTR) of c-myc.106,107  Labeled and unlabeled siRNA performed similarly 
in this study clearly demonstrating that the labeled and unlabeled siRNAs were equally capable of 
reducing protein expression, whereas the samples transfected with labeled and unlabeled 
scrambled control siRNAs showed no silencing of the targeted c-myc gene.  
Carboxyfluorescein (FAM) is another commonly used fluorescein derivative; its 
advantages include efficient synthetic incorporation, stability in water and excellent fluorescence 
emission quantum yields with limited photobleaching. FAM can bind to biological 
macromolecules by two carboxyl groups and be widely used for labeling proteins and nucleic acids 
in biomedical research.108,109 With siRNA therapeutics on the rise, companies like Glen Research 
and ChemGenes, among others, now offer numerous fluorescent probes within commercially 
available RNA phosphoramidites for their incorporation within RNA sequences by automated 
solid phase synthesis. (Figure 1.6) Examples include: fluorescein variants FAM (1.3), HEX (1.4), 
TET (1.5), ROX (1.6); cyanine dyes: Cy3 (1.7), Cy5 (1.8), and Cy7(1.9), Alexafluor (1.10; 
fluorescein replacement) and AquaPhlour® (1.11; Glen Research).  These products are designed 
to cover a wide range of fluorescence excitation and emission profiles making them extremely 
desirable to researchers.  
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Figure 1.6 Structures of Fluorescent Dyes utilized in Oligonucleotide Modifications 
 
As previously mentioned, FRET probes have significant utility in not only tracking siRNA 
transfection efficiency, but also siRNA stability within the cellular matrix. When two fluorophores 
1.3 1.4 
1.5 1.6 
1.7 1.8 
1.9 
1.10 1.11 
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(donor and acceptor) are in close proximity, excitation of the donor results in transmission of the 
energy to the acceptor, which emits light at longer wavelengths. If the light filter does not transmit 
the donor background emission, only acceptor fluorescence is seen when the donor is excited. 
FRET-based labeling and imaging allows for non-destructive and non-invasive assessment of the 
state of siRNAs in cultured cells. RNAi efficiency of siRNA duplexes is superior to ssRNA by 
several orders of magnitude110 clearly illustrating the importance of tracking the stability and 
location of the siRNA duplex in the cell. Labeling only one strand of the siRNA duplex does allow 
monitoring of siRNA transfection efficiency but provides limited information on siRNA based 
activity in live cells. Therefore, the use of FRET probes enabled siRNA mechanistic studies and 
imaging of its activity in live cells as well as in vivo.111-113   
 
 
 
 
Figure 1.7 Representation of FRET probe detection of siRNA duplex stability. Reprinted with 
permission from Springer Nature: Gruber, M.; Wetzl, B.; Oswald, B.; Enderlein, J.; Wolfbeis, O.S. 
J Fluoresc. 2005, 15 (3), 207-214.114 
18 
 
1.6 THESIS OBJECTIVES 
This thesis highlights significant advances in the field of siRNA functionalization for 
theranostic applications in the precision detection and treatment of cancer. The identification of 
the Glucose Regulated Protein of 78 kilodaltons (GRP78) as a biological marker in tumors that is 
typically over-expressed and cell surface localized on a variety of cancer cell types115,116 forms the 
basis of our cancer-targeted gene therapy strategy. In our novel approach, linear, V- and Y-shape 
siRNAs have been designed to target GRP78, GRP94 and GRP75, three main glucose regulated 
chaperones within the unfolded protein response system (UPR).116 The UPR is a cellular stress 
response related to the endoplasmic reticulum (ER) stress.117 The UPR is activated in response to 
an accumulation of unfolded or misfolded proteins in the lumen of the endoplasmic reticulum. The 
UPR has three aims: 1) to restore normal function of the cell by halting protein translation, 2) 
degrading misfolded proteins, and 3) activating the signaling pathways that lead to increasing the 
production of molecular chaperones involved in protein folding. If these objectives are not 
achieved within a certain time span or the disruption is prolonged, the UPR triggers cell-
based apoptosis. In this cancer intervention strategy, we aim to target and silence the three main 
GRPs within the UPR in an effort to potentiate a synergistic gene silencing effect which may lead 
to more effective cancer cell death.  
Chapter 2 of this thesis will focus on the initial development of our RNAi nanotechnology 
approach in which we designed V- and Y-shape RNA templates which held the propensity to self-
assemble into discrete, higher-ordered siRNA nanostructures targeting the oncogenic glucose 
regulated chaperones in a panel of cancer cell lines (Figure 1.8). These siRNAs self-assembled 
into genetically encoded spheres, triangles, squares, pentagons and hexagons of discrete sizes and 
shapes according to TEM imaging and DLS measurements. In a 24-sample siRNA screen 
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conducted within the AN3CA endometrial cancer cells known to overexpress tumorigenic GRP78, 
the self-assembled siRNAs targeting multiple sites of GRP78 mRNA demonstrated more potent 
and long-lasting anticancer activity relative to their linear controls. The self-assembled siRNA 
hybrids targeting of GRP-75, 78 and 95 resulted in significant (50- 95%) knockdown of the glucose 
regulated chaperones, which led to synergistic effects in tumor cell cycle arrest (50-80%) and death 
(50-60%) within endometrial (AN3CA), cervical (HeLa) and breast (MDA-MB-231) cancer cell 
lines. Taken together, these results validate that the self-assembled, GRP-targeting siRNA 
nanostructures exhibit potent silencing of GRP expression resulting in significant cell death effects 
in tumor cells that exhibit a strong dependence on GRP activity and the UPR.118 
 
Figure 1.8 Design and self-assembly of siRNA nanostructures. The RNA templates, namely, 
linear, V- and Y-shaped RNA were designed and synthesized according to our previously 
described methodology.11 The V- and Y-shaped templates incorporate a branchpoint ribouridine 
(rU) which facilitates the hybridization of complementary sense (S) and antisense (A) RNA. These 
templates preorganizes the self-assembly of siRNA hybrid nanostructures having discrete sizes 
and shapes, including those belonging to circles, triangles, squares, rectangles, pentagons, 
hexagons and porous-type structures. These siRNA nanostructures are genetically encoded to 
target a single (1), double (1, 2) and triple (1, 2, 3) sites of oncogenic GRP-75, 78 and 94 mRNA. 
Reprinted with permission: Patel MR, Kozuch SD, Cultrara CN, Yadav R, Huang S, Samuni U, 
Koren J 3rd, Chiosis G, Sabatino D. Nano Lett. 2016, 16(10), 6099–6108. Copyright 2016 
American Chemical Society. 
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Chapter 3 will focus on expanding the potential clinical utility of these V and Y-shaped 
higher ordered siRNA motifs while shedding insight into their mechanism of internalization and 
RNAi activity in live cancer cells with the incorporation of a fluorescent probe, FITC, covalently 
bound to the siRNA constructs (Figure 1.9). Interestingly, the fluorescent label is conjugated to 
the antisense strand, for linear and V-shaped hybrids, and the sense linear strands for Y-shaped 
hybrids. The fluorescently labeled siRNA were characterized by UV-Vis and fluorescence 
spectroscopy, which confirmed their photo-physical properties while PAGE, Tm and CD 
spectroscopy validated the hybrid stabilities and siRNA A-type helical structures for their RNAi 
applications in cancer cells. The fluorescently labeled antisense strand will potentially allow for 
extended fluorescence-based imaging of siRNA activity in live cells.  
 
Figure 1.9 Rational design of linear, V- and Y-shaped siRNAs containing a covalently linked 
FITC probe. Drawn with ChemDraw. 
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CHAPTER 2: DEVELOPMENT OF HIGHER-ORDER SIRNA HYBRIDS FOR RNAI 
MEDIATED CANCER GENE THERAPY 
2.1 Abstract 
With the rapid expansion and advances that have been made in the field of RNA 
nanotechnology, the ability to design single siRNA nanostructures that can deliver multiple 
siRNAs presents an intriguing opportunity for screening of a wide range of oncogene targets while 
potentiating cancer gene therapy effects. This chapter will discuss the optimized synthesis strategy 
of a branchpoint amidite which can be incorporated within the solid phase synthesis of RNAs for 
the rapid production of novel V- and Y-shaped RNAs. A 5’-OLv 2’-OMMT ribouridine 
phosphoramidite was synthesized by a three-step solution phase synthesis approach in which 
the 5’-OLv and 2’-OMMT served as orthogonal protecting groups for the selective construction 
of asymmetric V- and Y-shape RNA on solid support. Automated solid phase RNA synthesis 
was used to produce the requisite linear, V- and Y-shape RNA. Following isolation and 
characterization by RP IP HPLC and ESI MS, the RNAs were hybridized with their 
complementary single stranded RNA to form the siRNA hybrids. The siRNAs were further 
characterized by a combination of native PAGE, UV-Vis and CD spectroscopy which 
confirmed hybrid structures and stabilities for their RNAi applications. The V- and Y-shape 
RNA effectively served as templates for the self-assembly of hybrid siRNAs targeting multiple 
oncogenes related to overexpression of the Glucose Regulated Proteins (GRPs).  The GRPs 
function as chaperones mediating protein folding events in all cell types. In cancer, the GRPs 
are overexpressed and cell surface localized where they mediate tumorigenic behavior. In this 
study, the linear, V-, and Y-shape siRNAs adopted genetically encoded shapes targeting GRP-
75, 78 and 94 in a panel of tumorigenic cell lines.  More specifically, the self-assembled siRNA 
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hybrids (5 nM) resulted in significant (50-95%) knockdown of the selected GRPs, which led to 
synergistic effects in tumor cell cycle arrest (50-80%) and death (50-60%) within endometrial 
(AN3CA), cervical (HeLa) and breast (MDA-MB-231) cancer cell lines. Interestingly, a non-
cancerous lung (MRC5) cell line displaying normal GRP levels was found to tolerate siRNA 
treatment and demonstrated less toxicity (5-20%) relative to the cancer cells that were found to be 
addicted to the glucose regulated chaperones. These remarkable self-assembled siRNA 
nanostructures may thus encompass a new class of potent siRNAs that may be useful in screening 
important oncogene targets while improving siRNA therapeutic efficacy and specificity in cancer. 
2.2 Introduction 
Cancer gene therapy has gained a renaissance over the last few years due to the many advances in 
the areas of RNAi, plasmid DNA, CRISPR-Cas9 and CAR T cell technologies.1 In these applications, 
several cancer gene therapy strategies have been proven to be effective in vitro, and in vivo, paving the way 
for their successful applications in clinical trials.2 Among the most promising gene therapy approaches, the 
short-interfering RNA (siRNA) have been successfully applied in pre-clinical and clinical cancer therapy.3 
More specifically, modified siRNAs and their improved formulations have enhanced the knockdown effect 
of oncogenic mRNA resulting in potent tumor cell death responses.4 This RNA interference (RNAi) 
mechanism has shown exceptional catalytic efficacy and tolerance for a wide range of modified siRNAs 
including those incorporating modified nucleic acids, bioconjugation and self-assembly into higher order 
nanostructure formulations. The latter has effectively served to screen a variety of oncogene targets while 
potentiating gene silencing effects.5  
The rise of RNA nanotechnology has led to the development of multi-functional RNAs for a variety 
of applications, including the development of nanomedicines.6,7 Recently, siRNA nanostructures have been 
applied for multiple knockdown effects of gene targets. For example, RNA nanocubes composed of six 
double-stranded dsRNA Dicer substrates have been formulated and designed to release multiple siRNAs in 
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breast cancer cells.8 The intracellular release of the siRNAs was found to trigger the RNAi response for 
knockdown of the reporter, enhanced green fluorescent protein, (eGFP) for up to twelve days. In a related 
study, the multifunctional RNA nanorings containing six siRNAs within the nanoparticle formulation were 
shown to silence eGFP expression at concentrations as low as 1 nM over a nine-day period which 
outperformed the linear variants.9 Moreover, the siRNA nanoparticles were functionalized with RNA 
aptamers which displayed selective binding to the epidermal growth factor receptor (EGFR) overexpressed 
human breast cancer cells. In another proof-of-concept study, the branched siRNA nanostructures targeting 
multiple mRNA sites of the luciferase firefly reporter gene were shown to self-assemble into three- and 
four-way junctions.10 These nanoparticle formulations released multiple siRNAs upon Dicer cleavage and 
effectively silenced luciferase activity in HeLa cells. Taken altogether, these representative examples 
demonstrate the ability for higher-ordered siRNA nanostructures to release multiple siRNAs that ultimately 
lead to synergistic gene knockdown effects by the RNAi mechanism.  
We previously reported the synthesis, characterization and RNAi evaluation of branch and 
hyperbranched siRNAs.11 These novel siRNA structures were synthesized by automated solid phase RNA 
synthesis and incorporated a 5’-OLv 2’-OMMT ribouridine branchpoint synthon. The branchpoint synthon 
was composed of orthogonal protecting groups which facilitated the selective extension of three distinct 
RNA sequences targeting the Glucose Regulated Proteins (GRPs). In this preliminary study, GRP78 was 
selected as a client chaperone protein target which is located in the endoplasmic reticulum and plays a 
pivotal role in regulating protein misfolding by signaling the unfolded protein response (UPR) 
mechanism.12 While GRP78 is primarily found in the cytosol of healthy cells, in cancer, GRP78 is 
overexpressed and cell surface localized where it functions as a signaling receptor for tumorigenic 
activity.13  Moreover, GRP78 is associated with other stress-inducible members of the GRP family of 
chaperones, including GRP-75 and 94 which have also been found to play a pivotal role in the progression 
of certain types of cancers.19 GRP knockdown or inhibition has been shown to sensitize cancer cells to 
treatment, resulting in tumor cell cycle arrest and apoptosis in difficult to treat tumors.14-20 Thus, GRP78 
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and the related GRPs have been validated as clinically relevant targets for cancer detection and therapy.19 
In our previous study, the branch and hyperbranch siRNAs led to 50-60% silencing of GRP78 expression 
which translated to approximately 20% cell death of the HepG2 liver cancer cells.11 Therefore, the branch 
and hyperbranch siRNAs have effectively expanded the repertoire of modified siRNAs that may be useful 
in the development of more potent RNAi therapeutics.  
2.3 Chapter Objectives 
Towards this goal, this thesis chapter builds upon the pioneering work of Anthony Maina, 
Ph.D. and Mayurbhai Patel, Ph.D. which describes the synthesis, characterization and biological 
evaluation of a new class of high-ordered RNA structures. My contributions to these studies as 
described in this thesis chapter involve the optimization of the solution phase synthesis procedure 
for the generation of the requisite 5’-OLv 2’-OMMT ribouridine branchpoint phosphoramidite for 
its incorporation within V- and Y-shaped RNA templates. The V- and Y-shape RNA templates 
will then be synthesized by automated solid phase RNA synthesis, with selected modifications to 
the synthetic protocol11 in order to facilitate the efficient insertion, selective deprotection and RNA 
synthesis from the putative branchpoint synthon. Following synthesis, the RNA templates will be 
analyzed, purified and characterized by a combination of RP IP HPLC and ESI MS. 
Complementary, linear single stranded RNA will also be prepared by automated solid phase RNA 
synthesis for the self-assembly of GRP-targeting siRNA hybrids (Figure 2.1). This combinatorial 
self-assembly approach will enable the formulation of a library (30) of siRNA hybrids for 
exploring structure-activity relationships (SARs) within GRP overexpressing cancer cell lines.20 
Significantly, this study will demonstrate for the first time novel siRNA nanostructures that can 
effectively target and silence multiple oncogene targets within a selected panel of tumor cell lines. 
The latter provides a new contribution to modified siRNAs that can prove to be potent therapeutics 
in cancer gene therapy applications.   
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Figure 2.1.  Design and self-assembly of siRNA nanostructures. The RNA templates, namely, 
linear, V- and Y-shaped RNA were designed and synthesized according to our previously 
described methodology.11 The V- and Y-shaped templates incorporate a branchpoint ribouridine 
(rU) which facilitates the hybridization of complementary sense (S) and antisense (A) RNA. These 
templates preorganizes the self-assembly of siRNA hybrid nanostructures having discrete sizes 
and shapes, including those belonging to circles, triangles, squares, rectangles, pentagons, 
hexagons and porous-type structures. These siRNA nanostructures are genetically encoded to 
target a single (1), double (1, 2) and triple (1, 2, 3) sites of oncogenic GRP-75, 78 and 94 mRNA. 
Reprinted with permission: Patel MR, Kozuch SD, Cultrara CN, Yadav R, Huang S, Samuni U, 
Koren J 3rd, Chiosis G, Sabatino D. Nano Lett. 2016, 16(10), 6099–6108.20 Copyright 2016 
American Chemical Society. 
 
2.4 Results and Discussion 
2.4.1 Synthesis of 5’-OLv 2’-OMMT ribouridine branchpoint phosphoramidite 
The solution-phase synthesis of the requisite branchpoint amidite, 5’-O-levulinyl (Lv) 2’-O- 
monomethyoxytrityl (MMT) ribouridine phosphoramidite was completed by an optimized 
solution phase synthesis method based on literature precedence.11 The synthetic branchpoint 
amidite was obtained via a 3-step synthesis strategy featuring: (a) synthesis of levulinic 
anhydride followed by chemo-enzymatic levulination of the 5’ ribouridine hydroxyl group, (b) 
anomerically favored tritylation of the 2’ hydroxyl group and (c) phosphitylation of the 
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remaining 3’ hydroxyl group (Scheme 2.1). Synthesis of levulinic anhydride was achieved by 
reacting levulinic acid with dicyclohexylcarbodiimide (DCC) in diethyl ether until; 1) formation 
of insoluble dicyclohexylurea (DCU), 2) and changes in product mobility by thin-layer 
chromatography (TLC) were observed. Following reaction completion, the mixture was filtered 
to remove the DCU precipitate and subsequently evaporated to a viscous oil. The following step 
entailed the regio-selective chemo-enzymatic 5’-levulination of ribouridine using lipase acrylic 
resin from Candida antarctica.21 The levulinic anhydride is dissolved in anhydrous dioxane and 
added to a reaction vessel containing a slurry of the ribouridine starting material and the resin 
bound lipase suspended in dioxane. This reaction produced selectively the desired 5′-levulinyl 
ribouridine in 60-90% conversion (monitored by TLC) within 3 hours. Reaction with fresh 
enzyme afforded the higher yields with subsequent uses of the same batch of enzyme showing 
diminished conversions. This is due to the recovery of the enzyme once the reaction is complete. 
Previously methanol/ethanol were used to recover the enzyme as the unreacted ribouridine base 
is highly soluble in both those solvents; however, further research into the cause of the 
diminished yields revealed that upon washing the lipase bound enzyme, the short chain alcohols 
(methanol/ethanol) are suspected to occupy the active site of the enzyme, outcompeting 
substrate binding and limiting enzyme efficiency.22 According to literature, the enzyme regains 
some activity by washing the resin with a bulky alcohol, such as t-butanol. Purification of the 
desired 5’-O-Lv ribouridine was achieved via silica gel column chromatography with a gradient 
of 1-5% methanol (MeOH) in dichloromethane (DCM). Validation of the 5’-O-Lv ribouridine 
product was confirmed by 1H NMR and ESI-MS which validated the product, 2.2. The pure 5’-
O-Lv ribouridine was subsequently tritylated using monomethoxytrityl chloride (MMT-Cl), 
silver nitrate (AgNO3) and pyridine in tetrahydrofuran (THF) as the solvent.  The reaction was 
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performed in anhydrous conditions with nitrogen flushing the reaction flask for approximately 
15 minutes prior to reaction. The reaction proceeded smoothly at room temperature and yielded 
both the 2′ and 3′ tritylated regioisomers. The desired 2′-regioisomer, 2.4, was obtained in 
greater yields (50%) due to the enhanced nucleophilicity of the ribouridine 2′- vs. 3′-hydroxyl, 
which is in part related to the inductive effects of the neighboring anomeric nucleobase.23 The 
reaction proceeded to approximately 80% conversion (TLC analysis) in about 3-4 hours, with 
a product ratio of 2:1 in favor of the 2’ MMT regioisomer, 2.4. This reaction was monitored by: 
1) formation of insoluble silver chloride (AgCl) precipitate and 2) TLC indicating the 
conversion of the starting material, 2.2, to the more non-polar products, 2.3 and 2.4.  Upon 
completion of the reaction, the product was filtered to remove AgCl (s) and extracted in ethyl 
acetate (EtOAc) which was washed (NaHCO3(aq) and NaCl(aq)) and dried (MgSO4). Reaction 
analysis by TLC proved difficult due to the presence of pyridine. In this case, pyridine was 
found to migrate with the product making it difficult to determine conversion efficiency and 
establishing good eluent conditions for column chromatography. In our optimized method, 
pyridine removal was successively accomplished by washing the organic phase with a 10% 
aqueous copper(II) sulfate (CuSO4) solution
24 which effectively removed the latent pyridine 
from the solution. This allowed for more accurate TLC analysis. Purification of the desired 2’-
O-MMT regioisomer was therefore achieved via silica gel column chromatography using a 
gradient of 0-25% acetone in DCM with the desired 2’-O-MMT product being isolated in 45-
50% yields. The identity of the pure regioisomers was ascertained by 1H NMR, in which a 
COSY correlation cross-peak was used to explicitly assign the 3’-hydroxyl group (Figure 2.2).  
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Figure 2.2 1H-1H COSY NMR correlating the 3’ H with 3’ OH, 2.4 
 
In the final reaction step, the 5’-O-Lv, 2’-O-MMT ribouridine was phosphitylated using 
commercially available N,N-diisopropylamino cyanoethyl phosphonamidic-chloride, 
diisopropylethylamine (DIEA) in THF. The reaction was performed at room temperature under 
anhydrous conditions and the reaction progress was tracked by: 1) formation of the insoluble 
diisopropylethylamine-chloride salt, and 2) TLC. The reaction proceeded to approximately 80% 
conversion following 3-4 hr reaction, with the phosphoramidite diastereomers being observed 
as a single spot on TLC. Following solvent extraction, product washing and drying, the 
phosphoramidite diastereomers were dried to a viscous oil. The mixture was purified by silica 
gel column chromatography using a gradient of 20-45% acetone in hexanes with the 3’-
phosphoramidite product being isolated in 60% yield. To verify the identity of the 5′-O-Lv, 2′-
O-MMT, 3’-phosphoramidite product, 31P NMR confirmed the phosphoramidite diastereomers 
as two peaks (148.46 and 152.16 ppm) (Figure 2.3). The phosphoramidite diastereomers are 
perfectly amenable to solid phase RNA synthesis, in which during the synthetic cycle, the 
3’ OH 
3’ H 
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chirality at phosphorous is removed during the oxidation step. With the branchpoint 
phosphoramidite in hand, synthesis of V- and Y- shaped RNA was completed. 
 
 
 
Figure 2.3 31P NMR spectrum of the branchpoint phosphoramidite diastereomers, 2.5 
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Scheme 2.1. Synthesis of 5’-OLv 2’-OMMT ribouridine branchpoint phosphoramidite. Reaction 
and Conditions: (i). Lv2O, Candida antarctica Lipase resin, 1,4-dioxane, 22 
oC, 3 hrs, 2.2: 90%. 
(ii). MMT-Cl, AgNO3, THF, pyridine. 22
 oC, 3 hrs, 2.3: 25% and 2.4: 50%, (iii). Cl-
P(OCE)N(iPr)2, Et-N(iPr)2, THF, 22 °C, 3 hrs, 2.5: 70%. Drawn with ChemDraw. 
 
2.4.2 V-and Y-Shaped RNA Synthesis 
The automated solid phase RNA synthesis procedure and its extension into V- and Y-
shape RNA has been previously documented.11,20 Taking full advantage of this existing 
methodology, the synthesis of V-shape and Y-shape RNA templates along with their 
complementary RNA sequences were completed on solid-phase (Scheme 2.2). Briefly, the 
synthesis strategy involved automated RNA synthesis assembling commercially available 5’-
ODMT 2’-OTBDMS RNA phosphoramidites on the controlled pore glass (CPG) solid 
support.25 At the 5’-end of the linear RNA bound sequence, the 5’-OLv 2’-OMMT ribouridine 
branchpoint phosphoramidite was coupled using 5-ethylthiotetrazole (ETT) as activator and 
with an extended coupling time of 20 minutes (typical RNA amidites require 10 min coupling 
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times). Following branchpoint amidite coupling, a decyanoethylation step using 2:3 v/v 
triethylamine:acetonitrile (Et3N:MeCN) for 90 min was conducted to remove the phosphate 
backbone cyanoethyl protecting groups thereby converting the reactive phosphite triester to the 
more stable phosphite diester bond.26  Following decyanoethylation, the 2’MMT protecting 
group at the branchpoint position was removed using 3% DCA:DCM for 2 min to ensure 
complete detritylation at the more sterically encumbered 2’-position vs typical 5’-detritylation 
of the commercial RNA amidites. RNA synthesis from the liberated 2’-OH of the branchpoint 
synthon afforded the V-shape RNA template. Coupling times for the second RNA strand were 
increased from 10 to 22 min to ensure sufficient synthesis of the V-shaped RNA. A capping 
step, with acetic anhydride: N-methylimidizaole in pyridine was repeated twice to ensure 
complete acetylation of the terminal 5’-hydroxyl group of the V-shape RNA in order to prevent 
side-reactions or unwanted elongation of the RNA sequence. The 5’-Lv group at the 
branchpoint position was then selectively removed using 0.5 M hydrazine hydrate 
(NH2NH2
.H2O), buffered in 3:2 v/v pyridine:acetic acid for 20 min. Synthesis of the third RNA 
strand from the branchpoint 5’-position led to the generation of the Y-shape RNA template.  In 
the selection of our RNA sequences, they were designed to target complementary sites of GRP-
75, 78 and 94 mRNA expression in human cancer cells.27,28 Following solid phase synthesis, 
the linear, V-shape and Y-shape RNA templates were cleaved and deprotected from the solid 
support using 3:1 v/v NH4OH: EtOH at 60 ºC for 16 hrs. The 2’-TBDMS protecting groups 
were then desilylated using 1:1.5 v/v DMSO: TEA.3HF at 55 ºC for 2 hr. The crude RNA pellets 
were then precipitated in 3M NaOAc (25 µL) and n-BuOH (1 mL), isolated upon centrifugation 
and dissolved in autoclaved, Millipore H2O for analysis and purification. 
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Scheme 2.2: Solid-phase synthesis of V- and Y-shaped RNA templates. Drawn with ChemDraw 
 
2.4.3 Analysis, Purification and Characterization of siRNA hybrids 
 The RNA templates were quantified by UV-Vis spectroscopy, measuring the 
absorbance at ~260 nm which provides molar extinction coefficients associated with the π-π* 
and n-π* electronic transitions of the nitrogenous nucleobases and is directly correlated to 
sample concentration by the Beer-Lambert law.29 The RNA templates were subsequently 
analyzed and purified by RP IP HPLC30 (≥96%) and their identities were confirmed by 
electrospray ionization mass spectrometry (ESI MS),31 (Table 2.1).  
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Table 2.1. a Linear sequence number 1,2,3,7,19 and 21 represents antisense (A) siRNA sequence 
to its complimentary sense (S) sequences 4,5,6,8,20 and 22 respectively. V-shaped siRNA 
sequences 9-14 contains two siRNA sequences targeting GRP78 mRNA. Y-shaped siRNA 
sequences 15-18 contains three siRNA sequence targeting three different sites of GRP78 mRNA. 
Sequences 19-22 are linear siRNA sequences targeting GRP94 and GRP75. Sequences 23-25 are 
V-shape siRNA targeting two GRP mRNAs and sequence 26 is a Y-shape siRNA targeting three 
GRP mRNAs (GRP78, GRP94, GRP75).  b Determined by UV-Vis Spectroscopy. c Obtained by 
RP-IP-HPLC using 0.1 mM TEAA in 0-20% MeCN, pH: 7.2 over 26 min. d Calculated mass 
(observed mass) by ESI-MS in negative mode (Novatia LLC, Newton, PA). Reprinted with 
permission: Patel MR, Kozuch SD, Cultrara CN, Yadav R, Huang S, Samuni U, Koren J 3rd, 
Chiosis G, Sabatino D. Nano Lett. 2016, 16(10), 6099–6108. Copyright 2016 American Chemical 
Society. 
 
Furthermore, a denaturing urea PAGE gel was used to confirm the relative 
electrophoretic mobilities of the RNA templates.32 In this study, the linear RNA sequences 
migrated the fastest on gel whereas the lengthier, bulkier V- and Y-shape RNA templates were 
found to be more retained on the gel. The RNA templates were hybridized with their 
complementary strands in annealing buffer (10 mM Tris, 50 mM NaCl, 1 mM EDTA, pH 7.5–
8.0). Hybridization and self-assembly were promoted by heating the RNA templates and their 
complementary sequences at 9 0ºC (5-10 min) followed by slow cooling to room temperature 
(22 ºC) for 1 hr, and overnight storage at 4 ºC. siRNA hybridization efficiency was confirmed 
by a native, non-denaturing 16% PAGE. The lower molecular weight templates (linear, V- and 
Y-shape RNA) migrated fastest on the gel and were found to be equivalent to the observed 
migration of the 23-50 bp RNA ladder. The V-and Y-shaped RNA templates hybridized to their 
complementary RNA single strands and migrated slower on the gel, with electrophoretic 
mobilities comparable to the migration of the 30-50 bp RNA ladder and the 150-300 bp RNA 
ladder. The self-assembled V- and Y-shape siRNA hybrids migrated the slowest on the gel. The 
self-assembled V-shape siRNA hybrids migrated with similar electrophoretic mobility when 
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compared to the V-shape siRNA hybrids formed with their complementary linear RNA 
sequences. The siRNA hybrid combinations formed with multiple Y- and V-RNA templates 
were found to be ≥300 bp RNA ladder suggesting the formation of higher-ordered siRNA 
nanostructures (Figure 2.4). 
 
Figure 2.4 siRNA self-assembly. Native, non-denaturing 16% PAGE. (A) V-shape (lanes 12-14) 
and Y-shape (lanes 8-11) RNA templates and the self-assembled V- (lanes 4-7) and Y-shape (lanes 
2-3) siRNA hybrids. (B) Linear (lanes 26, 27), Y-shape (lanes 22-25) RNA templates and the self-
assembled Y-shape (lanes 16-21) siRNA hybrids. (C) Linear (lanes 38-41), V-shape (34-37) RNA 
templates and the self-assembled V-shape (lanes 28-33) siRNA hybrids. The RNA ladder (23-
500bp) was used to track the relative sizes of the siRNA hybrids on the gels (lanes 1 and 15). 
Reprinted with permission: Patel MR, Kozuch SD, Cultrara CN, Yadav R, Huang S, Samuni U, 
Koren J 3rd, Chiosis G, Sabatino D. Nano Lett. 2016, 16(10), 6099–6108. Copyright 2016 
American Chemical Society. 
 
In order to study the structural properties of hybrid siRNAs, CD spectroscopy was used 
to assess changes (if any) in the typical A-type helical structure anticipated from double-
stranded RNA hybrids. The A-type RNA helices contain a minimum peak at 240 nm and a 
broad maximum in between 250-290 nm.33 In the case of the self-assembled V- and Y-shape 
siRNA hybrids (Figure 2.5), the A-type broad maximum and minimum bands were observed 
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in between 250-290 nm and 240 nm, respectively, albeit with a decrease in the amplitudes of 
the molar ellipticities at these characteristic wavelengths. In these cases, minor distortions in 
the A-type helical trajectory were observed with the V- and Y-shape siRNA hybrids, 
presumably due to the conformational constraints imparted by the branchpoint synthon.11,20 
Despite this change, the self-assembled V- and Y-shape siRNA hybrids maintained CD 
signatures that were consistent with the A-type RNA helix (Figure 2.3). 
 
 
Figure 2.5 Circular dichroism spectroscopy of V- and Y-shaped siRNAs. All hybrid siRNA 
samples were prepared by annealing equimolar quantities (0.75 nM) of antisense V-shaped (A) or 
Y-shaped (B) RNA templates with their complementary linear or V- or Y-shaped RNA sequences. 
Samples were hybridized in annealing buffer (10 mM Tris, 50 mM NaCl, 1 mM EDTA, pH 7.5–
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8.0, 13-15 μL)  by pre-heating at 95 oC (3-5 min) followed by slow cooling to rt over 1 h and 
overnight storage at 4 oC prior to CD analyses. All samples were diluted in annealing buffer (1 
mL) and the CD analysis was observed from 205-310 nm. Reprinted with permission: Patel MR, 
Kozuch SD, Cultrara CN, Yadav R, Huang S, Samuni U, Koren J 3rd, Chiosis G, Sabatino D. 
Nano Lett. 2016, 16(10), 6099–6108. Copyright 2016 American Chemical Society. 
 
siRNA hybrid stabilities were then measured by thermal denaturation (Tm) (Figure 2.4). 
In this assay, the observed melting temperature (Tm) reflects the temperature at which 50% of 
the hybrids have denatured into single strands. Consequently, the higher the Tm the more 
thermally stable the siRNA hybrid. In this study, the siRNA hybrids based on the V-shape RNA 
templates were found to be very stable, with high Tm values for the A11:S11 (Tm = 84ºC) and 
A12:S12 (Tm = 78ºC). The V-shaped RNA templates hybridized with their complementary 
linear strands showed good thermal stabilities (A11:S1S1, Tm = 76ºC and A12:S1S2, Tm = 
77ºC). Similarly, the siRNA hybrids, A111:S111 and A123:S123, based on the Y-shape RNA 
templates were also found to be stable, Tm = 69 ºC and Tm = 63 ºC, respectively. The Y-shaped 
RNA template hybridized to its complementary linear RNA strands formed siRNA hybrids 
which maintained good thermal stabilities (A111:S1S1S1, Tm = 62 ºC and A123:S1S2S3, Tm 
= 68 ºC). Taken together, the linear, V- and Y-shape siRNA hybrids maintained good thermal 
stability, indicating their potential applicability to cell biology under physiologically relevant 
conditions (pH~7, T: 37 oC). 
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A. 
 
B. 
 
Figure 2.6 Thermal denaturation of V- and Y-shaped siRNAs. All sample hybrids were prepared 
by annealing equimolar quantities (0.75 µM) of antisense V-shaped (A) or Y-shaped (B) RNA to 
their complementary single or V- or Y-shaped RNA template strands. Samples were hybridized in 
anealing buffer (10 mM Tris, 50 mM NaCl, 1 mM EDTA, pH 7.5–8.0, 13-15 μL)  by pre-heating 
at 95 oC followed by slow cooling to rt over 1 h and overnight storage at 4 oC prior to Tm analyses. 
Before running Tm, all samples were diluted in annealing buffer (1 mL) and the Tm analyses were 
observed at 260 nm between temperatures of 5-95 oC. Reprinted with permission: Patel MR, 
Kozuch SD, Cultrara CN, Yadav R, Huang S, Samuni U, Koren J 3rd, Chiosis G, Sabatino D. 
Nano Lett. 2016, 16(10), 6099–6108. Copyright 2016 American Chemical Society. 
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2.4.4 RNAi activity of GRP-targeting siRNA hybrids in human cancer cell lines 
In collaboration with Drs. Gabriela Chiosis and John Koren 3rd, the RNAi activity of the 
siRNA hybrids were studied in human cancer cell lines at the Memorial Sloan Kettering Cancer 
Center (MSKCC) in New York, NY. The GRP overexpressing human cervical HeLa,27 
endometrial AN3CA34-40 and breast MDA-MB-23141 cancer cells in addition to a 
nontumorigenic lung fibroblast MRC542 cell line displaying normal GRP function were used as 
representative models to assess the influence of the glucose regulated chaperones, GRP-75, 78 
and 94 on cell viability. The most potent anticancer effects were observed with the tri-functional 
Y-shape siRNA targeting GRP-75, 78 and 94. In this case, potent (50-95%) knockdown was 
observed in all cancer cell lines which translated to significant levels of tumor cell cycle arrest 
(50-80%) and cancer cell death (50-60%). In comparison, the multiple GRP78-targeting Y-
shape siRNA (A123:S1S2S3) triggered only about 10% AC3CA cell death whereas the GRP-
75, 78 and 94 targeting Y-shape siRNA produced a 5-fold increase (50%) in cytotoxicity at low 
doses of 5 nM. Moreover, GRP knockdown with the GRP-75, 78 and 94 targeting Y-shape 
siRNA had a more pronounced effect on tumor cell growth inhibition (50-80%) and death (50-
60%) when compared to the control, non-tumorigenic MRC5 cell line which displayed modest 
growth inhibition (10-30%) and death (10-20%) (Figure 2.5). These results correlate an 
addiction of human cancer cells to the overexpressed glucose regulated chaperone which may 
contribute towards cancer treatment selectivity.43 Therefore, the self-assembled siRNA hybrids 
targeting multiple GRPs proved useful in screening these important oncogene targets for 
elucidating their role on cancer cell biology while improving siRNA therapeutic efficacy and 
specificity in cancer. 
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Figure 2.7 RNAi screening. (A) GRP mRNA levels detected by RT-PCR. HeLa cells were 
transfected with NS RNA, linear GRP(78+94+75) and Y-shape GRP(789475) siRNA (5 nM) using 
RNAiMAX™ (7 µL). GRP78, GRP94, GRP75, and GAPDH mRNA levels were normalized 
according to GAPDH and quantitated with respect to NS RNA. (B) LDH Release Assay. The % 
LDH released was measured following transfections of all treated cell lines (MRC5, AN3CA, 
MDA-MB-231 and HeLa). The LDH levels were quantitated and normalized according to the NS 
RNA. (C) Western blots measuring GRP78, GRP94 and GRP75 (% protein) levels following 
siRNA (5 nM) transfections in normal lung, MRC5, endometrial, AN3CA, breast, MDA-MB-231 
and cervical, HeLa cancer cells. The GRP78, GRP94 and GRP75 levels were normalized 
according to GAPDH and quantified with respect to the NS RNA. Data represents knockdown 
efficiency of V-shape siRNAs (GRP7894, GRP7875, GRP9475), Y-shape siRNA (GRP789475) 
and the linear siRNAs (GRP78+GRP94+GRP75) added in combination. All experiments were 
replicated in triplicates with average values presented with their standard deviations about the 
mean. Statistical analyses produced error bars with acceptable variance ±SEM; N = 3, p < 0.05. 
Reprinted with permission: Patel MR, Kozuch SD, Cultrara CN, Yadav R, Huang S, Samuni U, 
Koren J 3rd, Chiosis G, Sabatino D. Nano Lett. 2016, 16(10), 6099–6108. Copyright 2016 
American Chemical Society. 
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2.5. Conclusions 
 
This study demonstrated the rational design and applications of RNA templates in the 
self-assembly of higher order siRNA hybrids for RNAi screening of the GRP oncogenes and 
cancer gene therapy applications. The novel V- and Y-shape siRNA hybrids described in this 
thesis chapter were shown, through thermal denaturation and CD spectroscopy respectively, to 
confirm the prerequisite siRNA hybrid stabilities and A-type helices for invoking RNAi 
activity. In an RNAi screen across a panel of GRP overexpressing cancer cell lines and a non-
tumorigenic control cell line displaying normal levels of GRP, the multi-functional Y-shape 
siRNAs targeting GRP-75, 78 and 94 mRNA oncogenes displayed synergistic anticancer effects 
which superseded the siRNAs targeting GRP78 alone. The RNAi screen also revealed the 
influence of GRP activity on cell viability. The GRP overexpressing cancer cells were 
sensitized to GRP-75, 78 and 94 knockdown resulting in greater tumor cell cycle arrest and 
cytotoxicity relative to the non-tumorigenic control. In conclusion, these novel siRNA motifs 
encompass a new class of bio-probes for studying RNAi activity in cancer and for screening 
important (single or multiple) oncogene targets for successful applications in cancer gene 
therapy. 
2.6 Experimental  
2.6.1 General Methods   
Chemical synthesis reagents and solvents were obtained from ChemGenes, Glen Research, 
Aldrich and VWR and used as received. Solid phase oligonucleotides synthesis reagents and 
materials were obtained from ChemGenes or Glen Research Inc. and also used without further 
purification. HPLC grade solvents for chromatography were purchased from EMI Biosciences. 
Analytical thin-layer chromatography (TLC) was performed on aluminum-backed silica gel plates 
(Merck 60 F254). TLCs were visualized under UV shadowing (260 nm) or staining (10% 
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H2SO4/MeOH). Compound purification using silica gel chromatography was performed on 230-
400 mesh silica (Sorbent Technologies). Molecular weights for 2.2-2.5 were measured as direct 
injections on a Hewlett Packard series 1100 MSD equipped with ESI as ion-source in positive 
mode using 50/50 v/v MeOH/H2O at a flow-rate of 1 mL/min. Nuclear magnetic resonance spectra 
(1H, 13C, 31P COSY, HMQC NMR) were recorded on an Varian NMR AS500 spectrophotometer. 
The NMR spectra were obtained at ambient temperature using either an indirect pulse-field 
gradient (ID-PFG) or a switchable pulse-field gradient (SW-PFG) probe. The obtained data was 
processed using VNMRJ software (version 2.2). The 1H and 13C assignments were based on 
gCOSY and gHMQC NMR correlation experiments.  
2.6.2 Synthesis  
5’-O-levulinyl ribouridine (2.2): Levulinic acid (7.5 mL, 74 mmol) and N,N-
dicyclohexylcarbodiimide (DCC) in dichloromethane (DCM, 15.2g) were stirred together in 150 
mL of anhydrous diethyl ether to generate levulinic anhydride (Lv2O). The reaction was run at 
room temperature (22 °C) under N2 atmosphere for 5 hours. The byproduct (DCU) was removed 
by vacuum filtration and the filtrate was evaporated into viscous oil. In a second flask, ribouridine 
(3.0 g, 12.3 mmol) was vacuum dried for 5 hours and flushed with nitrogen before being suspended 
in 50 mL of anhydrous dioxane with resin-bound lipase enzyme, Candida Antarctica 435 (3 g). 
Crude Lv2O was dissolved in dioxane (150 mL) and added to the flask containing the ribouridine 
and enzyme in dioxane. The chemo-enzymatic reaction was run for 3-4 hours at 22 °C (room 
temperature) under N2. The reaction progress was monitored by TLC (10% MeOH in DCM) which 
confirmed ~90% conversion of starting material to product and the appearance of two non-polar 
products (Rf: 0.83 and 0.724). The resin-bound lipase was filtered, washed (MeOH) and recycled 
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for additional use. The filtrate was concentrated and purified by silica gel column chromatography 
(1-10% MeOH: DCM) to isolate the product in 60% yield.  
1H NMR (2.2, 500 MHz, DMSO-d6): δ 11.31 (1H, s, NH), 7.88 (1H, d, J = 10 Hz, H6), 5.77 (1H, 
d, J = 7 Hz, H5), 5.64 (1H, d, J = 9 Hz, H1’), 5.37 (1H, d, J = 7.5 Hz, H5’), 4.14 (1H, dd, J = 12, 
7.5 Hz, H5”), 4.06 (1H, t, J = 10 Hz, H2’), 3.95 (1H, bs, H3’), 3.32 (1H, s, H4’),  2.69 (2H, s, Lv 
CH2), 2.37 (2H, s, Lv CH2), 2.09 (3H, s, Lv CH3); 
13C NMR (2.2, 500 MHz, DMSO-d6): δ 207.2 
(CO), 172.7 (CO), 163.6 (CO), 151.1 (CO), 146.0 (C6), 107.2 (C5), 89.05 (C1’), 81.57 (C4’), 
73.31 (C2’), 70.16 (C3’), 64.12 (C5’), 37.76 (CH2), 29.8 (CH2), 27.90 (CH3); ESI-MS [M]-: Calcd. 
for C14H18N2O8 : 341.3, found : 341.0. 
5’-O-levulinyl 2’-O-monomethoxytrityl ribouridine (2.4) and 5’-O-levulinyl 3’-O-
monomethoxytrityl ribouridine (2.3): A tritylation reaction was conducted using nucleoside 2.2 
(2.52 g, 7.37 mmol), monomethoxytrityl chloride, MMT-Cl (2.73 g, 10.6 mmol) and silver nitrate 
(1.5 g, 10.6 mmol) which were dried under vacuum overnight before dissolving the reagents in 
pyridine (6.5 mL) under nitrogen at room temperature (22 °C). The reaction was run for 3 h and 
tracked by TLC (20:80 MeCN:DCM) which confirmed the presence of the 2’ and 3’-OMMT 
regioisomers, Rf (2.4): 0.5 and Rf (2.3): 0.36, respectively. The reaction mixture was then diluted 
with ethyl acetate (EtOAc) (60 mL) and washed twice with saturated sodium bicarbonate 
(NaHCO3) (60 mL). The organic layer was separated and dried using anhydrous sodium sulfate 
(Na2SO4). The solvent was evaporated and the crude product purified by silica gel column 
chromatography (5-50% MeCN:DCM). The presences of pyridine in the reaction complicated the 
spotting on TLC, so a TLC plate pre-stained with 10% sulfuric acid in methanol was used to detect 
the product by detritylating the yellow colored MMT+ group. The 5’-O-levulinyl 2’-O-
monomethoxytrityl ribouridine, 2.4, eluted first and was dried as a white foam in yields of 30%. 
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The identity of the 3’-OMMT regioisomer was confirmed by 1H-1H COSY NMR which indicated 
a correlation cross-peak between the 3’H and 3’-OH in 2.4. 
1H NMR (2.4, 500 MHz, DMSO-d6): δ 11.32 (1H, s, NH), 7.52-6.81 (14H, m, MMT), 7.14 (1H, 
d, J = 8 Hz, H6), 5.92 (1H, d, J = 7 Hz, H1’), 5.43 (1H, dd, J = 8 Hz, H5), 5.22 (1H, d, J = 7 Hz, 
3’OH), 4.21 (1H, t, J = 6 Hz, H2’), 4.0 (2H, m, H5’), 3.88 (1H, dd, J = 12 Hz, H4’), 3.71 (3H, s, 
OMe), 3.03 (1H, td, J = 6.5 Hz, H3’), 2.69 (2H, t, J = 7 Hz, Lv CH2), 2.38 (2H, td, J = 6.5 Hz, Lv 
CH2), 2.09 (3H, s, CH3); ESI-MS [M]
-: Calcd. for C34H34N2O9
- : 613.7, found: 613.3. 
5’-O-levulinyl 2’-O-monomethoxytrityl 3’-O-phosphoramidous ribouridine (2.5) Isolated 
tritylated nucleoside 2.4 was reacted separately in a phosphitylation reaction by first drying the 
tritylated nucleoside (1.31 g, 2.13 mmol) overnight prior to reaction. Dry tetrahydrofuran (THF) 
(15 mL) was added to the nucleoside under a flow of nitrogen and N,N-diisopropylethylamine 
(DIEA) (1.48 mL, 8.50 mmol) and the phosphitylating reagent, Cl-P(OCEt)N(i-Pr)2 (650 µL, 2.34 
mmol) was to the flask. The reaction was stirred for 3 h at room temperature and monitored by 
TLC (45% Acetone: Hexanes) until the formation of the phosphoramidite diastereomers was 
observed, Rf (2.5) 0.60. A white precipitate, EtNH(iPr)2
+ Cl-, was also observed as an indication of 
reaction completion. Upon reaction completion, EtOAc (60 mL) was added to the reaction mixture 
prior to washing twice with saturated NaHCO3 (30 mL). The organic phase was dried over Na2SO4 
and concentrated to a yellowish foam. The crude product was purified by silica gel 
chromatography (20-45% Acetone: Hexanes).  Product 2.5 was collected, dried as a white foam in 
yields of 60%. 31P NMR (2.5, 400 MHz, DMSO-d6): 151.56 and 148.35; ESI-MS [M]
-: Calcd. for 
C43H51N4O10P: 813.87, found: 813.3. 
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2.6.3 Solid phase RNA synthesis  
RNA was synthesized on an automated ABI 3400 synthesizer. Reagents for the synthesis 
cycle were as follows: detritylation reagent (3% solution of dichloroacetic acid in 
dichloromethane), coupling reagent (0.25 M ethylthiotetrazole in acetonitrile), capping reagent 
(Cap A: 1:1:8 v/v/v acetic anhydride:pyridine:tetrahydrofuran, Cap B: 16% N-methyl imidazole 
in tetrahdrofuran), oxidation reagent (0.02 M iodine in 75:20:5 v/v/v 
tetrahydrofuran:pyridine:water) and acetonitrile wash (Biotech grade purchased from EMI). 
Oligonucleotide syntheses were performed on a 1 µmol scale using 1000 - 2000 Å LCAA CPG. 
RNA phosphoramidites were prepared as 0.15 M solutions in anhydrous acetonitrile with coupling 
times of 10 min. For the synthesis of branch RNA, the branchpoint phosphoramidites (2.5) were 
also prepared as 0.2 M solutions in MeCN and coupled with an extended reaction time of 20 min. 
RNA syntheses were performed using the following synthesis cycle: Detritylation: 
Dichloromethane wash (30s) followed by delivery of 3% dichloroacetic acid in dichloromethane 
(120s); Coupling: delivery of RNA phosphoramidites with activator (0.25 M ethylthiotetrazole in 
acetonitrile), Capping:, delivery of Cap A and Cap B (14 sec) and Oxidation: delivery of oxidizing 
solution (0.02 M iodine in 75:20:5 v/v/v tetrahydrofuran:pyridine:water) for 20 sec followed by a 
wait period of 20 sec. Single stranded RNA sequences were extended in the 3’5’ orientation on 
solid-phase until completion.  
V- and Y-shape RNA were first grown in the 3’5’ position followed by coupling of the 
branchpoint phosphoramidite 2.5. The branchpoint phosphoramidite was coupled for 20 min, 
followed by a manual decyanoethylation step (2:3 v/v triethylamine:acetonitrile, 90 min) prior to 
the 2’-OMMT detritylation. The oligonucleotide bound CPG was washed with acetonitrile (30 
mL) and replaced on the synthesizer to complete 3’5’ RNA synthesis of the antiparallel 
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complimentary strand. The terminal 5’-OH was then capped with automated delivery of Cap A 
and Cap B (14 sec). Following V-shape RNA synthesis, 2.9, the 5’-levulinyl protecting group was 
removed by flushing the column with 0.5 M hydrazine hydrate buffered in 3:2 v/v pyridine:acetic 
acid (20 min). Following delevulination, the CPG-bound V-shape RNA was cleaved and 
deprotected from the solid support for analysis and purification. For Y-shape RNA, automated 
RNA synthesis was continued from the branchpoint 5’-OH to yield branch RNA 2.10.  
2.6.4 Cleavage and deprotection of RNA  
Cleavage and deprotection of the synthesized RNA was performed after drying the 
synthesizer columns under Ar(g) for 10 min. CPG-bound RNA was then transferred into autoclaved 
screw-cap microtubes (1.5 mL) and treated with a 1 mL solution of 3:1 v/v ammonium hydroxide 
in absolute ethanol at 55 oC for 16 to 20 hrs. RNA samples were then evaporated in-vacuo and the 
CPG was washed twice with autoclaved distilled water (500 µL). Crude oligonucleotides were re-
suspended in a mixture of 1:1.5 v/v dimethylsulfoxide:triethylamine trihydrofluoride (150 µL) to 
complete the 2’-desilylation reaction at 65 °C for 2 hr. The crude RNA samples were subsequently 
precipitated from the reaction mixture with 3 M NaOAc (25 µL) in n-BuOH (1 mL). Precipitation 
was completed in freezer (-80 °C) on dry ice for 30min prior to centrifugation (12,000 rpm) leaving 
the crude oligonucleotides as a solid white pellet. The collected RNA samples were dried in a 
Speedvac concentrator and re-suspended in autoclaved water (1 mL) for yield determination using 
UV absorbance measurements at 260 nm.  
2.6.5 Polyacrylamide gel electrophoresis (PAGE)  
siRNA samples (Table, 2.1, sequences 1-26) were analyzed using denaturing PAGE. 
Analytical samples were prepared by drying 0.1 OD (A260) overnight and re-suspending the sample 
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in a denaturing formamide solution (80% formamide in 10X TBE buffer) prior to loading on the 
gel. Samples were loaded (20 µL/well) along with dye solution (5 µL of 10 mL formamide mixed 
with trace amounts of bromophenol blue and xylene cyanol) to track gel migration. The gels were 
run at 300 V, 100 mA and 12 W for 3 h in 1X TBE running buffer on a 7 M urea (21 g), 24% 
polyacrylamide gel. Gels were visualized under short range (265 nm) UV-shadowing and 
subsequently placed in a Stains-All® (Sigma) solution (25 mg Stains-All®, 50 mL isopropyl 
alcohol, 25 mL formamide, 125 mL water). After 2 h, the gel was removed from the stain solution 
and exposed to light for analyses. 
Pure siRNAs (Table, 2.1, sequences 1-26) were analyzed by native PAGE. Purified 
complementary RNA strands were combined in equimolar quantity (20uM) and mixed in 
annealing buffer (25 µL, 10 mM Tris, 50 mM NaCl, 1 mM EDTA, pH 7.5–8.0) to afford the hybrid 
mixtures. The resulting mixtures were heated to 95ºC for 7 minutes on a heating block, slowly 
cooled to room temperature (22ºC) over 1 h and stored in the fridge overnight at 4 ºC prior to 
analysis. The hybridized siRNA samples were suspended in 30% sucrose loading buffer (15 μL in 
1X TBE). Samples were then loaded on a 16% native, non-denaturing PAGE and run at 300 V, 
100 mA and 12 W for 2.5 h. Following electrophoresis, the siRNA bands were visualized under 
UV shadowing (260 nm) and stained with a Stains-All (Sigma-Aldrich™) solution. 
2.6.6 Ion pairing reverse phase HPLC (IP RP HPLC)  
 All samples (Table, 2.1, sequences 1-26) were analyzed by IP RP HPLC to determine 
purity. HPLC was performed on a Waters® 2695 Alliance Separations Module. Crude samples 
were dissolved in autoclaved water (0.1 OD for analytical) and injected into a Waters Symmetry 
C-18 reverse phase column (4.6 x 150 mm, 5 µm particle size, 120 Å) using a gradient of 5-95% 
(20% acetonitrile in 0.1 M triethylammnonium acetate) at 60 oC with a flow rate of 1 mL/min over 
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26 min at 260 nm. Peak areas were calculated to determine percent purity of samples. IP RP HPLC 
was used to confirm siRNA purities >90% following purification. 
2.6.7 Electrospray ionization mass spectrometry (ESI MS) 
 siRNA samples (0.1-0.4 µM) were dissolved in autoclaved water and analyzed by mass 
spectrometry. Samples were analyzed by Dr. Mark Hail at Novatia LLC, Newton, PA, utilizing 
Oligo HTCS equipped ESI/MS in negative mode. The data was obtained and deconvoluted using 
ProMass software. Theoretical molecular weights were calculated by entering each sequence 
identity on IDT OligoAnalyzer. https://www.idtdna.com/calc/analyzer 
2.6.8 CD Spectroscopy 
siRNA samples were hybridized in annealing buffer (0.75 µM, 10 mM Tris, 50 mM NaCl, 
1 mM EDTA, pH 7.5–8.0, 1 mL) as previously described. Samples were then transferred to fused 
quartz cells (1 cm path length) incubated at 10 °C under N2 for 5 min prior to spectral acquisition. 
CD spectra were collected using an AVIV 62A DS CD spectrophotometer as an average of 3 scans 
with a 1.0 nm band width interval and a 0.5 nm step interval. CD spectra were analyzed in between 
210 and 310 nm, blank corrected and smoothed prior to analyses. The raw data was exported into 
Microsoft Excel™ and plotted as changes in molar ellipticities (θ) with increasing wavelengths 
(210 – 310 nm). 
2.6.9 Thermal Denaturation (Tm) studies 
  All siRNA hybrids were prepared as previously described in annealing buffer (0.75 µM, 
10 mM Tris, 50 mM NaCl, 1 mM EDTA, pH 7.5–8.0, 1 mL). Thermal denaturation of the siRNA 
hybrids was performed using a CARY 3E, UV-Vis spectrophotometer, from 5 – 95 °C, with 
temperature ramping of 0.5 °C /min. The changes in absorption at 260 nm as a function of 
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temperature were collected and the first derivative plot was used to determine the melting 
temperatures (Tm) of the siRNA samples. Data was subsequently transferred and plotted in 
Microsoft Excel™ as changes in the hyperchromicities (% H) observed at 260 nm as a function of 
temperature (5 – 95 °C).  
2.6.10 Cell Culture 
 The human normal lung cells MRC5 (ATCC® CCL-171™), endometrial cancer cells 
AN3CA (ATCC® HTB-111™), breast cancer cells MDA-MB-231 (ATCC® HTB-26™) and 
cervical cancer cells HeLa (ATCC® CCL-2™) were purchased from ATCC. MDA-MB-231, HeLa 
and MRC5 cells were cultured in Dulbecco’s Modified Eagle medium (DMEM) while AN3CA 
cells were in Minimum Essential Medium (MEM) supplemented with 10% (v/v) Fetal Bovine 
Serum (FBS) and 1% (v/v) Penicillin/streptomycin (P/S) under 5% CO2 at 37 °C.  For passaging 
cells were detached with 0.25% trypsin and re-suspended with complete culture medium. 
2.6.11 siRNA Transfections in AN3CA Cells  
Briefly, the AN3CA endometrial cancer cells (ATCC® HTB-111™), 1 x 105, were plated 
in 6-well culture plates containing MEM culture media with 10% FBS. Cells were cultured for 48 
h in a humidified incubator set at 37 °C with 5% CO2. Prior to transfections, the siRNA hybrids (5 
L, 2.5-12.5 M, in DMEM, 250 L) were mixed with the transfection reagents (Lipofectamine 
2000™, Silentfect™ or RNAiMAX™, 2.5 – 7 L in DMEM, 250 L) according to the 
manufacture’s recommendation. The mixtures were incubated (10 min, 22oC) then added to the 
AN3CA cell culture and incubated at 37 °C with 5% CO2 over a three-day period. Cell growth 
over time (65-72 h) was monitored in an Incucyte™ (Essen BioScience). 
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2.6.12 RNA isolation and quantitative RT-PCR 
GRP mRNA was isolated from the HeLa cervical cancer cell lines using the manufacturer’s 
protocol (TRIzol®, ThermoFisher Scientific). The RNA pellet was dissolved in 
diethylpyrocarbonate-treated H2O. The total mRNA levels were quantitated by measuring the 
absorbance of collected RNA samples at 260 nm. The isolated RNAs (1.5 µg of each sample) were 
treated with gDNA Wipeout buffer at 42 °C to eliminate residual genomic DNA. These samples 
were then reverse-transcribed using Quantiscript reverse transcriptase, Quantiscript RT Buffer, 
and RT Primer Mix according to manufacturer’s protocol (QIAGEN). Additionally, the samples 
were incubated with RNaseH to remove RNA, and the resulting cDNAs were then diluted to 100 
µL with distilled water. Each quantitative PCR consisted of 5 µL of cDNA template, 12.5 µL of 
PerfCta SYBR Green Supermix, Low ROX (Quanta Biosciences, Beverly, MA), and 500 nM of 
forward and reverse primers in a ﬁnal volume of 25 µL. For human GRP78, the primer sequences 
were 5'-ACCTCCAACCCCGAGAACA-3' (forward) and 5'-TTCAACCACCTTGAACGGC-3' 
(reverse). For human GRP94, 5'-ACTGTTGAGGAGCCCATGGAGG-3' (forward) and 5'-
GCTGAAGAGTCTCGCGGGAAAC-3' (reverse). For human GRP75, 5’-
AGCTGGAATGGCCTTAGTCAT-3’ (forward) and 5’-CAGGAGTTGGTAGTACCCAAATC-
3’ (reverse). For GAPDH, the primer sequences were 5'-ACCACAGTCCATGCCATCAC-3' 
(forward) and 5'-TCCACCACCCTGTTGCTGTA-3' (reverse). The reactions were carried out on 
an ABI PRISM 7000 sequence detection system (Applied Biosystems, Foster City, CA) for 30 
cycles (95 °C for 15 sec, 60 °C for 45 sec) after an initial 3 min of incubation at 95 °C. The fold 
change in the expression of each gene was calculated using the standard curve method, with 
GAPDH used as an internal control for normalization. 
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2.6.13 Western Blots 
The cell media was aspirated from the transfected culture and washed with PBS buffer for 
2-3 min, twice.  The cells were lysed using cell lysis buffer (1% Tween-20, 50 mM Tris, 130 mM 
NaCl, 5 mM EDTA) containing protease inhibitors and phosphatase inhibitors (Protease inhibitor, 
PSMF, Phos2, Phos3).  Protein concentration of lysates were determined using the BSA protein 
assay reagent (ThermoFisher Scientific Inc.). Proteins samples (15-20 mg, 20 µL) were dissolved 
in 5X loading buffer, boiled for 5-7 min, and resolved in 10% sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE). The proteins were electrotransferred onto a 
polyvinylidene difluoride membrane (Bio-Rad Laboratories), which was blocked in Tris-buffered 
saline, pH 8.0, Tween-20, 5% (w/v) skimmed milk (TBST solution) for 1 h at room temperature 
(22 oC). Membranes were then probed with the indicated primary antibodies (anti-PARP p85 
fragment pAb, Promega Inc. and anti-GRP78 pAb, Cell Signaling Inc.) in TBST solution at 4 °C 
overnight.  Next day, membranes were washed with TBST solution (3X, 10 min each) and 
incubated with horseradish peroxidase (HRP) conjugated secondary antibodies (1:3000) at room 
temperature for 1 h followed by washing with TBST solution (3X, 10 min each). Immunoblotted 
protein bands were visualized by enhanced chemiluminescence reagent (ThermoFisher Scientific) 
and quantified using NIH imager (ImageJ) 
2.6.14 Cell Cytotoxicity 
Following transfection with GRP78 specific siRNAs, a cytotoxicity assay was performed 
with all cells using the Cytotoxicity Detection Kit (ThermoFisher Scientific Inc.). With this kit, 
the rate of cell lysis is monitored by determination of the LDH amount released into the culture 
medium and quantified at 492 nm by the detection of the red formazan chromophore.  
 
57 
 
2.7 References 
1. Naldini, L. Nature 2015, 526, 351-360. 
2. Ajith, T. A. J. Exp. Ther. Oncol. 2015, 11, 33-39. 
3. Masiero, M.; Nardo, G.; Indraccolo, S.; Favaro, E. Mol. Aspects Med. 2007, 28, 143-166. 
4. Lam, J. K.; Chow, M.Y.; Zhang, Y.; Leung, S. W. Mol. Ther. Nucleic Acids. 2015, 4, e252. 
5. Gaglione, M.; Messere, A. Mini Rev. Med. Chem. 2010, 10, 578-595. 
6. Guo, P. Nat. Nanotechnol. 2010, 5, 833-842. 
7. Shukla, G. C.; Haque, F.; Tor, Y.; Wilhelmsson, L. M.; Toulmé, J. J.; Isambert, H.; Guo, P.; 
Rossi, J. J.; Tenenbaum, S. A.; Shapiro, B. A. ACS Nano. 2011, 5, 3405-3418. 
8. Afonin, K. A.; Viard, M.; Kagiampakis, I.; Case, C. L.; Dobrovolskaia, M. A.; Hofmann, J.; 
Vrzak, A.; Kireeva, M.; Kasprzak, W. K.; KewalRamani, V. N.; Shapiro, B. A. ACS Nano. 
2015, 9, 251-259. 
9. Afonin, K. A.; Viard, M.; Koyfman, A. Y.; Martins, A. N.; Kasprzak, W. K.; Panigaj, M.; 
Desai, R.; Santhanam, A.; Grabow, W. W.; Jaeger, L.; Heldman, E.; Reiser, J.; Chiu, W.; 
Freed, E. O.; Shapiro, B. A. Nano Lett. 2014, 14, 5662-5671. 
10. Nakashima, Y.; Abe, H.; Abe, N.; Aikawa, K.; Ito, Y. Chem. Commun. 2011, 47, 8367-8369. 
11. (a) Maina, A.; Blackman, B. A.; Parronchi, C. J.; Morozko, E.; Bender, M. E.; Blake, A. D.; 
Sabatino, D. Bioorg. Med. Chem. Lett. 2013, 23, 5270-5274., (b) Maina, A. Branching into 
RNAi: Synthesis, Characterization and Biology of Branch and Hyperbranch siRNAs. Ph.D. 
Thesis 2014, Seton Hall University, South Orange, New Jersey. 
12. Lee, A.S. Curr. Opin. Cell Biol. 1992, 4, 267-273. 
13. Zhang, L. H.; Zhang, X. J. Cell Biochem. 2010, 110, 1299-1305. 
14. Roller, C.; Maddalo, D. Front Pharmacol. 2013, 4, 10. 
15. Chang, Y. J.; Huang, Y. P.; Li, Z. L.; Chen, C. H. PLoS One. 2012, 7, e35123. 
16. Dejeans, N.; Glorieux, C.; Guenin, S.; Beck, R.; Sid, B.; Rousseau, R.; Bisig, B.; Delvenne, 
P.; Buc, Calderon, P.; Verrax, J. Free Radic. Biol. Med. 2012, 52, 993-1002. 
17. Yi, X.; Luk, J.M.; Lee, N.P.; Peng, J.; Leng, X.; Guan, X.Y.; Lau, G.K.; Beretta, L.; Fan, S.T. 
Mol. Cell Proteomics. 2008, 7, 315-25. 
18. Firczuk, M.; Gabrysiak, M.; Barankiewicz, J.; Domagala, A.; Nowis, D.; Kujawa, M.; 
Jankowska-Steifer, E.; Wachowska, M.; Glodkowska-Mrowka, E.; Korsak, B.; Winiarska, M.; 
Golab, J. Cell Death Dis. 2013, 4, e741. 
19. Lee, A. S. Nat. Rev. Cancer 2014, 14, 263-276. 
20. (a) Patel MR, Kozuch SD, Cultrara CN, Yadav R, Huang S, Samuni U, Koren J 3rd, Chiosis 
G, Sabatino D. Nano Lett., 2016, 16, 6099–6108., (b) Patel, M.R.. RNAi Nanotechnology: A 
Platform for siRNA Screening and Gene Therapy. Ph.D. Thesis 2016, Seton Hall University, 
South Orange, New Jersey. 
21. Kirk, O.; Christensesn, M.W. Org. Proc. Res. Dev., 2002, 6, 446–451. 
22. Chen, J.W.; Wu, W.T.; J Biosci and Bioeng. 2003, 95, 466-469 
23. Wilkinson, K.A.; Merino, E.J.; Weeks, K.M. Nature 2006, 1, 1610-1616. 
24. Vedejs, E.; Fuchs, P.L. J. Org. Chem., 1971, 36, 366–367. 
25. Iwai, S.; Sasaki, T.; Ohtsuka, E. Tetrahedron 1990, 46, 6673-6688. 
26. (a) Damha, M.J.; Braich, R.S. Tetrahedron Lett. 1998, 39, 3907-3910, (b) Braich, R.S.; Damha, 
M.J. Bioconjugate Chem. 1997, 8, 370-377. 
27. Suzuki, T.; Lu, J.; Zahed, M.; Kita, K.; Suzuki, N. Arch. Biochem. Biophys. 2007, 468, 1-14. 
58 
 
28. Saar Ray, M.; Moskovich, O.; Iosefson, O.; Fishelson, Z. J. Biol. Chem. 2014, 289, 15014-
15022. 
29. Porterfield, J.Z.; Zlotnick, A. Virology. 2010, 407, 281-288. 
30. (a) McCarthy, S.M.; Gilar, M.; Gebler, J. Anal. Biochem. 2009, 390, 181-188, (b) Noll, B.; 
Seiffert, S.; Vornlocher, H.-P.; Roehl, I., J. Chromatogr. A 2011, 1218, 5609-5617. 
31. Beverly, M.; Hartsough, K.; Machemer, L.; Pavco, P.; Lockridge, J., J. Chromatogr. B 2006, 
835, 62-70. 
32. (a) Petrov, A.; Tsa, A.; Puglisi J.D.  Methods Enzymol. 2013, 530, 301-313, (b) Petrov, A.; Wu, 
T.; Puglisi, E.V.; Puglisi, J.D. Methods Enzymol. 2013, 530, 315-30. 
33. Gray, D.M.; Hung, S.H.; Johnson, K.H. Methods Enzymol. 1995, 246, 19-34. 
34. Gray, M. J.; Mhawech-Fauceglia, P.; Yoo, E.; Yang, W.; Wu, E.; Lee, A. S.; Lin, Y. G. Int. J. 
Cancer. 2013, 133, 21-30. 
35. Bifulco, G; Miele, C; Di Jeso, B; Beguinot, F; Nappi, C; Di Carlo, C; Capuozzo, S; Terrazzano, 
G; Insabato, L; Ulianich, L. Gynecol. Oncol. 2012, 125, 220-225. 
36. Ulianich, L; Insabato, L. Front. Med. 2014, 1, 55-60. 
37. Matsuo, K; Gray, M. J; Yang, D. Y; Srivastava, S. A; Tripathi, P. B; Sonoda, L, A; Yoo, E. I; 
Duebeau, L; Lee, A. S; Lin, A. S. Gynecol. Oncol. 2013, 128, 552-559. 
38. Luvsandagya, B.; Nakamura, K.; Kitahara, Y.; Aoki, H.; Murata, T.; Ikeda, S.; Minegishi, T. 
Gynecol. Oncol. 2012, 126, 132-139. 
39. Wang, H.; Liu, Z.; Gou, Y.; Qin, Y.; Xu, Y.; Liu, J.; Wu, J. Z. Int. J. Nanomedicine 2015, 10, 
5505-5512. 
40. Calì, G; Insabato, L; Conza, D; Bifulco, G; Parrillo, L; Mirra, P; Fiory, F; Miele, C; Raciti, G. 
A; Di Jeso, B; Terrazzano, G; Beguinot, F; Ulianich, L. J. Cell. Physiol. 2014, 229, 1417-1426/ 
41. Dejeans, N.; Glorieux, C.; Guenin, S.; Beck, R.; Sid, B.; Rousseau, R.; Bisig, B.; Delvenne, 
P.; Buc Calderon, P.; Verrax, J. Free Radic. Biol. Med. 2012, 52, 993-1002 
42. Rubporn, A.; Srisomsap, C.; Subhasitanont, P.; Chokchaichamnankit, D.; Chiablaem, K.; 
Svasti, J.; Sangvanich, P. Cancer Genomics Proteomics. 2009, 6, 229-237. 
43. Taldone, T.; Ochiana, S.O.; Patel, P.D.; Chiosis, G. Trends Pharmacol. Sci. 2014, 35, 
592603. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
59 
 
CHAPTER 3: FLUORESCENTLY LABELED SIRNAS AND THEIR THERANOSTIC 
APPLICATIONS IN CANCER GENE THERAPY 
 
3.1 Abstract 
Gene therapy has emerged as a promising precision nano-medicine strategy in the targeted 
detection and therapy of cancer. The integration of therapy and diagnostics “theranostics” have 
gained significant traction in the development of new and improved gene therapeutics that 
effectively diagnose and treat cancers at the onset of the disease. At the forefront of its pre-clinical 
and clinical applications are the short-interfering RNA (siRNA), that have silenced oncogenic 
mRNA expression of oncoproteins leading to cancer cell death through the RNA interference 
(RNAi) mechanism. Our research program focuses on the development of siRNAs designed to 
target and silence the expression of the Glucose Regulated Proteins (GRPs). The GRPs are a class 
of chaperone proteins assisting in protein folding events within the endoplasmic reticulum. Under 
physiological or pathological stress conditions, some GRPs translocate to the cell surface where 
they function as receptors signaling oncogenic activity. Therefore, the GRPs have been classified 
as clinically viable therapeutic targets. In the theranostic approach presented in Chapter 3 of this 
thesis, the covalent attachment of a fluorophore, fluorescein isothiocyanate (FITC), is applied for 
monitoring cell uptake, co-localization and biological activity of a wide range of GRP-silencing 
siRNAs, including those adopting linear, V-shape and Y-branch nanostructures. The incorporation 
of the FITC reporter did not perturb the requisite A-type helix structure required for siRNA activity 
as verified by CD spectroscopy. Furthermore, FITC did not inhibit hybrid duplex stability, verified 
by Tm, although some degree of fluorescence quenching relative to the unlabeled siRNA was 
detected by spectrofluorimetry. In an attempt to overcome the quenching effect, the higher-order 
V- and Y-shape siRNAs enabled the incorporation of multiple FITC reporters; however, the 
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incorporation of multiple FITC probes did not overcome the quenching effects in vitro. In cells, 
the silencing efficiency of the FITC-labeled siRNAs within a prostate cancer cell line (PC-3, 
ATCC® CRL-1435™) was determined via RT-PCR. In all cases, FITC-siRNA hybrids (50nM) 
exhibited less mRNA knockdown (~10-30%) when compared to their non-labeled counterparts 
(~40-80%). Conjugation of the FITC probe to the sense strand of the siRNAs re-established mRNA 
knockdown (~50-<90%) efficiency which also translated to more potent cell death over a 72 hr 
period (~20-95%). Cell uptake of the multi FITC-labeled V- and Y-shape siRNAs was monitored 
via flow cytometry which revealed rapid cell internalization (2-4 hrs) and enhanced fluorescent 
signaling which remained present within the cells post transfection (72 hrs). Western blot analysis 
of the lead Y-shaped FL-siRNA showed protein level silencing of GRP78 and GRP75 (~40%), 
while qRT-PCR showed mRNA silencing of GRP78 and 94 (~40-60%). Taken together, the data 
presented within this chapter outlines the potential utility of FL-siRNAs as potent theranostic 
agents for cancer gene therapy. 
3.2 Introduction 
3.2.1 SiRNAs as Theranostic Agents 
 “Theranostics” is a term that refers to the simultaneous integration of diagnosis and therapy 
in the detection and treatment of a wide range of diseases, including cancer.1 Nano-theranostics 
characterizes nanoparticle formulations that have gained widespread utility in the development of 
nano-medicine strategies for advanced theranostic applications. Ultimately, the purpose is to 
diagnose and treat diseases at their earliest stages, when they are most likely curable or at least 
treatable. Nano-theranostic approaches can be promising treatment options, even for the most 
lethal or difficult to treat diseases such as cancer, cardiovascular diseases and AIDS.2,3 Advanced 
theranostic nano-medicines are multifunctional in nature, capable of diagnosis and delivery of 
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therapy to the diseased cells with the incorporation of targeting ligands, biomarkers and reporter 
probes that enable detection.4-6 (Figure 3.1) The therapeutic agent can encompass a small molecule 
synthetic drug or complex natural product, synthetic, semi-synthetic and recombinant biologics, 
toxins and suicide substrates or irreversible inhibitors. The diagnostic agent can include a 
fluorescent reporter, a radionuclide, near IR sensors and contrast agents that have also received 
widespread use in pre-clinical and clinical applications (Figure 3.1). Theranostic nano-medicines 
are robust, biocompatible and non-toxic delivery platforms that can sustain controlled release, 
targeted delivery and higher transport efficiency by receptor mediated endocytosis at the target 
site.7  For example, stimulus responsive delivery agents have led to the development of triggered 
release (i.e., smart delivery)8  and synergistic performance in combination therapy strategies (i.e. 
siRNA co-delivery with other therapeutics).9  
Acting as a multimodal therapy strategy, siRNA based theranostics have been shown to 
greatly improve the diagnosis and therapy of many disease types, including cancer.9 In this 
multimodal approach, iron oxide nanoparticles were developed for simultaneous in vivo imaging 
and siRNA delivery into tumors by high resolution MRI and near infrared (NIR) in vivo optical 
imaging.10 The siRNA, coupled with aminated dextran particles, myristoylated polyarginine 
peptide, a membrane translocation peptide, and the NIR dye Cy5.5 were all conjugated to the 
surface of an iron oxide nanoparticles. Tracking these probes in vivo by MRI and NIR fluorescence 
optical imaging, the delivery of siRNA and its silencing efficiency of Survivin genes in glioma 
tumors was monitored for 48 h by dextran coated iron oxide nanoparticles. Drug loaded quantum 
dots have also been used as theranostic agents in which solid lipid nanoparticles were combined 
with the chemotherapeutic paclitaxel, also known as Taxol®, and Bcl-2 targeted siRNA into 
human lung carcinoma cells.11 The prepared solid lipid nanoparticles loaded with the combined 
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paclitaxel/siRNA complexes exhibited synergistic anticancer activities by triggering caspase-
mediated apoptosis. The strong fluorescence intensity of quantum dots within solid lipid 
nanoparticles enabled in situ visualization and intracellular translocation of solid lipid 
nanoparticles in A549 lung cancer cells.  
Theranostic approaches to cancer treatment have also shown to be successful in silencing 
oncogene expression in aggressive forms of cancers.12 In this application, a near-infrared (NIR) 
fluorescent polymer capable of in vivo siRNA delivery was used to simultaneously track tumor 
accumulation by noninvasive NIR imaging. Systemic siRNA delivery using the polyPCPDTBT 
polymer-NIR nanoparticle formulation resulted in efficient silencing of V-Raf expression of 
murine sarcoma viral oncogene homolog B (BRAF) in anaplastic thyroid cancer (ATC) tumor 
tissues and significantly suppresses tumor growth and metastasis in an orthotopic mouse model.  
Carbon dots (Cdots) are currently emerging as a class of promising fluorescent probes 
because of their low photobleaching and optical blinking, tunable photoluminescence, versatile 
surfaces, and excellent biocompatibility.13,14  Cdot based nanocarriers have been developed to 
delivery siRNA against anti-apoptotic protein, Survivin, in human gastric cancer cell line MGC-
803.15  It is well known that Survivin plays an important role in regulating cell division, apoptosis, 
and checkpoint mechanisms of genomic integrity.16,17  In addition, Survivin expression is often 
upregulated in human cancers, as it can be treated as a specific tumor marker with prognostic and 
therapeutic implications from studies of gastric carcinomas.18  The siRNA-Cdot complex was 
rapidly accumulated into the MGC-803 cells within 2 h. Blue fluorescence from Cdots and red 
fluorescence from labeled siRNA increase significantly in a time dependent manner. SiRNA-Cdots 
complexes, which target Survivin, exhibited potent mRNA and protein knockdown which induced 
63 
 
apoptosis and cell cycle arrest in G1 phase in human gastric cancer cells MGC-803. The resulting 
Cdots-based delivery system may be used to advance the field of siRNA therapeutics.  
SiRNAs conjugated to dual-purpose superparamagnetic iron oxide nanoparticles (SPIONs) 
were evaluated as theranostic agents against pancreatic ductal adenocarcinoma (PDAC).19 
Multifunctional theranostic probes comprising of dextran-coated SPIONs that were easily detected 
by MRI imaging. These probes were functionalized with: (i) the non-immunogenic ligand EPPT120 
specifically targeting the tumor antigen under glycosylated MUC1 (uMUC1), which is a hallmark 
of early pancreatic tumorigenesis and abundantly and ubiquitously expressed in PDAC; (ii) 
myristoylated polyarginine peptides (MPAPs)21 to enhance cellular uptake and mediating the 
endosomal escape of siPLK1 into the cytoplasm; and (iii) siPLK1, for selective silencing of 
siPLK1 to halt cell cycle progression selectively in the tumor.22 Administrations of these 
complexes in tumor-bearing mice allows monitoring of  the delivery agent to the tumor site by 
MRI resulting in efficient silencing of the target gene, PLK1. This approach can significantly 
advance the therapeutic potential of siRNAs by providing an effective way to shuttle siRNAs to 
target sites and to non-invasively access therapeutic efficacy of the siRNAs by monitoring tumor 
growth. 
SiRNAs have also been designed to target Pim-1, a serine/threonine kinase that 
phosphorylates heterochromatin protein HP1γ  and several other targets, for example, cdc25 and 
c-Myb24-26 is involved in the induction of B cell lymphoma when co-expressed together with c-
Myb.27  In addition, Pim-1 seems to play a role in cell survival, differentiation, and 
proliferation.28,29  SiRNAs targeting Pim-130 exhibited excellent silencing efficiency of a Pim1-
green fluorescent protein (GFP) fusion gene at low nanomolar  concentrations (5 nM). PsiR4 was 
labeled with Cy3 at the 5' -end of the sense strand to investigate cellular uptake and localization in 
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living COS-7 and F-11 cells. Cellular uptake of the Cy3-labeled siRNA by lipofection was 
observed in more than 90% of the cells post transfection (4-6 hr). Fluorescence imaging revealed 
strong inhibition of Pim1-GFP expression at a concentration of 10 nM, with nearly complete Pim-
1 silencing at a concentration of 50 nM, while western blot analysis confirmed the knockdown of 
Pim-1 with PsiR4-Cy3 at the protein level. These results show that PsiR4-Cy3 is a useful molecule 
to study siRNA uptake and localization in living cells. 
Fluorescently labeled siRNAs have also been used to optimize knockdown efficacy.30 
SiRNA labeled with FITC at either the 5′-end of the sense or the antisense strand were compared 
with un-transfected or mock transfected cells with unlabeled siRNA. In this instance, distinct 
intracellular fluorescence staining was observed in cells transfected with FITC labeled siRNA. 
These signals showed intracytoplasmic and perinuclear localization, in accordance with the current 
notion of RNAi occurring as a post-transcriptional process. No qualitative difference was observed 
between sense and antisense-labeled siRNA molecules.  
Taken together, these selected examples serve to highlight the fruitful applications of 
theranostic siRNA formulations that have enabled detection and treatment in difficult to treat 
cancers in vitro and in vivo by selectively targeting and silencing oncogenic mRNA expression. 
Moreover, the theranostic siRNA formulation can be fine-tuned to incorporate noninvasive 
reporter probes for tracking biological activity in live cancer cells and within in vivo xenograft 
models, as well as chemotherapeutics, which potentiates the anti-cancer effects when used in 
combination treatment regimens. As such, the multifunctional siRNA theranostic formulations 
have shown success in difficult to treat tumors, while also minimizing relapse and the evolution 
of treatment resistance. The latter is a primary goal in the development of effective precision 
medicine approaches.      
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Figure 3.1 Mutifunctional applications of theranostic agents. Wang, J.; Cui, H. 
Theranostics. 2016, 6 (9), 1274-76.31 
 
3.2.2 The Glucose Regulated Proteins as Therapeutic Targets 
The glucose-regulated protein (GRPs) are chaperone proteins that serve as the main sensors 
for misfolded proteins in the endoplasmic reticulum (ER) and trigger the unfolded protein response 
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(UPR) under physiological and pathological cellular stress conditions.32 GRPs are found in the 
lumen of the ER or the mitochondria where they own important functions in the regulation of 
protein folding events that are necessary for cell homeostasis and survival. As chaperones, GRPs 
are subcellularly localized in the ER where they chaperone protein folding activity, in the 
mitochondria where they interact with pro-apoptotic executors and at the cell surface where they 
direct cell signaling.33 Cell surface GRPs have been found on a variety of cancer cells but not on 
normal ones, thereby making them valuable biomarkers for the development of targeted forms of 
cancer therapy (Table 3.1).34-37  
Glucose-regulated protein 78 (GRP78), also known as the immunoglobulin heavy chain 
binding protein (BiP), is a member of the heat-shock protein (HSP) family of chaperones that 
mainly resides in endoplasmic reticulum (ER).38 GRP78 is an important regulator of ER 
homeostasis due to its role in protein folding and assembly while targeting misfolded proteins for 
degradation.39 Numerous studies have shown that cells under physiological or pathological ER 
stress, such as hypoxia, acidosis and glucose deprivation, elicit upregulation of GRP78.40,41 
Upregulation of GRP78 is commonly associated with tumor cell apoptosis resistance,42 drug 
resistance,43 tumor adhesion, migration and metastasis.44 Furthermore, studies have shown that 
downregulation of GRP78 can promote apoptosis and inhibit tumor growth.45,46  Our group has 
shown that targeting and silencing GRP78 expression in HepG2 liver cancer cells resulted in 
noticeable albeit minimal (5-15%) cell death.47  More importantly, cancer cell surface GRP78 is 
associated with pathological stress induced conditions that are typically associated with the tumor 
microenvironment.48,49  In addition, the cell surface GRP78 often presents in the form of clustering 
or punctate aggregates associated with carcinogenesis.50  Taken together, cell surface GRP78 has 
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been classified as a biomarker which serves as a receptor for oncogenic signaling and as a target 
for GRP78-dependent gene therapy in cancer cells exhibiting GRP78 overexpression.  
Similarly, GRP94 has been found to maintain ER Ca2+ homeostasis and confer cancer cells 
protection from apoptosis.51  Alternatively, GRP94 suppression or knockdown in patient derived 
multiple myeloma samples was found to trigger apoptosis by inhibition of the WNT–survivin 
pathway.52  Furthermore, in the absence of GRP94, the multiple myeloma cells were found to 
undergo mitotic destruction, which resulted in cell death and correlated with a decreased 
expression of Survivin.53  Therefore, GRP94 might promote survival and progression of multiple 
myeloma as well as in other, related tumors.  For example, induction of GRP94 in HeLa cells was 
observed following transfection with 2'-O-methyl-modified siRNA targeting GRP78 mRNA. 
GRP94 induction was hypothesized to play a compensatory role in maintaining UPR activity.  
GRP75, a homologue of HSP70 has been found to interact with the tumor suppressor p53, 
leading to the inhibition of p53 function and induction of apoptosis.54  Furthermore, cell surface 
GRP94 and GRP170 function in antigen presentation, and their secreted forms have the ability to 
stimulate immune responses, which could be useful in the development of cancer vaccines.55  In 
cancer cells, GRP170 is upregulated by hypoxia and by drugs such as celecoxib (a non-steroidal 
anti-inflammatory drug) and proteasome inhibitors, and knockdown of GRP170 activated the 
expression of the UPR pro-apoptotic factor CHOP and stimulated apoptosis.56 Therefore, GRP170 
might also protect cancer cells against cell death by blocking ER Ca2+  release or delaying the onset 
of the UPR by binding to the ER stress sensors.57 Therefore, the GRPs encompass an important 
class of tumor-promoting genes whose downregulation has been found to confer potent anti-cancer 
effects in a panel of cancer cell lines.58 Towards this effect, we have demonstrated that silencing 
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GRP 75, 78 and 94 in endometrial, cervical and breast cancer resulted in potent GRP knockdown 
and cell death relative to a non-tumorigenic cell line which displayed normal GRP expressions.  
 
Table 3.1 Overexpression of GRPs in different cancer types. Adapted with permission from 
Springer Nature: Lee, A.S. Nat. Rev. Cancer 2014, 14, 263-276. 
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3.3 Project Objectives 
In an effort to build on previous work from our group, this chapter describes the design, 
synthesis, characterization and biological evaluation of fluorescently labeled siRNA 
nanostructures within human cancer cells. The project objectives for this study begins with the 
selection of the lead linear, V- and Y-shaped siRNAs that elicited the most potent silencing 
efficiency when targeting one or two sites of oncogenic GRP78 and those related to the GRP-75 
and 94 mRNA sequences. The solid-phase RNA synthesis strategy based on our previous study47 
was used to generate V-shape and Y-branch RNA templates using the ribouridine branch-point 
synthon (Figure 3.2). The lead linear, V- and Y-shaped RNAs were functionalized with an amino 
modified hexamethylene linker, which facilitated conjugation of the reporter fluorescent probe. 
The amino modified sequences were then coupled to fluorescein isothiocyanate (FITC) following 
a previously reported method.59  Following coupling, RP-IP-HPLC and ESI-MS were used to 
characterize the purity and identity of the RNA templates. The hybrid fluorescently-labeled 
siRNAs (FL-siRNA) were characterized by Polyacrylamide Gel Electrophoresis (PAGE), Thermal 
Denaturation (Tm) and Circular Dichroism Spectroscopy (CD). Fluorescence emissions and 
quantum yields (ɸ) of the FL-siRNA constructs were also determined in order to evaluate the 
overall efficacy of the functionalized siRNAs as molecular beacons. Biological evaluation and 
uptake efficiency of the linear, V- and Y-shaped FL-siRNA constructs were determined within the 
PC-3 human prostate cancer cell line. Silencing efficiency of the siRNA constructs was determined 
at the mRNA and protein levels by qRT-PCR and western blot, respectively. Whereas, time-
dependent cellular uptake efficiency was evaluated by flow cytometry and fluorescence 
microscopy. To assess the toxicity effects of the fluorescently labeled siRNAs, cell viability was 
determined using propidium iodide (PI) staining.  
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Figure 3.2. Rational design of FL-siRNA bioconjugates. Linear, V-shape and Y-branch GRP 
silencing siRNAs with A) single and B) multiple FITC probes. Drawn in ChemDraw. 
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3.4 Results and Discussion 
3.4.1 FITC Solid Phase RNA Bioconjugation 
As a representative example, the amino functionalized RNA template, 3.1, was subjected to a 
solid-phase bioconjugation reaction for the attachment of the fluorescent probe, fluorescein 
isothiocyanate (FITC). Based on literature precedence,59 the attachment of FITC was achieved by 
reacting FITC in 20% aqueous DMF mixed in 0.1M carbonate-bicarbonate buffer (pH 8.5) onto 
the amino modified RNA template bound to the solid support (Scheme 3.1). Following reaction, 
FL-RNA sample, 3.2, was cleaved and deprotected from the solid support for analysis and 
purification. 
 
Scheme 3.1 Solid phase bioconjugation of linear, V- and Y- shape FITC-RNA bioconjugates. 
Drawn in ChemDraw. 
3.1 3.2 
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3.4.2  Analysis and Purification of FITC-RNA Templates 
The RNA templates described in this study (Table 1) are based on the target sequences for 
downregulating GRP-75, 78 and 94 expression in human cancer cells.46,60  The linear, V- and Y-
shaped RNA templates were synthesized by semi-automated solid phase RNA synthesis following 
our previously reported procedure.47  The RNA templates were purified by Reverse-Phase Ion-
Pairing High Performance Liquid Chromatography (RP IP HPLC) in ≥95% purities and their 
identities were confirmed by electrospray ionization mass spectrometry (ESI MS) (Table 3.2). 
Purified FL-RNA templates were then quantitated by UV-Vis spectroscopy at 260 nm which also 
confirmed the absorption of FITC (460-490 nm). Denaturing PAGE analysis of the purified RNA 
templates suggested some degradation, however, RP IP HPLC re-analysis of the sequences 
confirmed pure RNA samples. Presumably, denaturing PAGE conditions produced some sample 
degradation, albeit minimal (Figure 3.4). Moreover, UV shadowing of the gel revealed FITC 
fluorescence for the labeled RNA templates (Figure 3.4B). However, the analysis did reveal that 
the FITC-Y shaped RNA was not present. The reaction was conducted multiple times in an effort 
to obtain the FITC-Y shaped siRNA, however, none were successful. To address this problem, 
attachment of the FITC probe to the corresponding complementary linear sense strands was 
achieved in high yields and purities >95%, allowing further characterization to be conducted with 
the fluorescently-labeled Y-shape siRNA hybrid.  
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Table 3.2.  aLinear, V- and Y-shaped RNA sequences designed to target GRP-78, 94 and 75. b 
Determined by UV-Vis Spectroscopy. c Obtained by RP-IP-HPLC using 0.1 mM TEAA in 0-45% 
MeCN, pH: 7.2 over 20 min. d Calculated mass (observed mass) by ESI-MS in negative mode 
(Novatia LLC, Newton, PA). * Sample purchased from ChemGenes (Wilmington, MA) 
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12 
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Figure 3.3 Denaturing PAGE of FITC-labeled siRNAs. Sequences in green represent FITC 
labeled sequences: Lane 1: Dye; Lane 3 GRP78A1; Lane 4 FITCGRP78-A1; Lane 5 V-
78A194A1; Lane 6 FITC-C6-V-78A194A1; Lane 7 FITC-V-78A194A1 (peak1); Lane 8 FITC-V-
78A194A1 (peak2); Lane 9 V-78A178A2; Lane 10 FITC-V-78A178A2; Lane 11 FITC-V-
78A194A1 (peak1); Lane 12 FITC-V-78A194A1 (peak2); Lane 13 Y-78A194A175A1; Lane 14 
FITC-Y-78A194A175A1; Lane 15 Dye.  
 
3.4.3 FITC-siRNA Hybridization and Native PAGE 
The RNA templates were hybridized with their complementary strands in the annealing 
Tris buffer buffer (10 mM Tris, 50 mM NaCl, 1 mM EDTA, pH 7.5 – 8.0) conditions. siRNA 
hybridization and self-assembly was confirmed by a native, non-denaturing 16% polyacrylamide 
gel electrophoresis (PAGE). In this assay, (Figure 3.5A) the lower molecular weight linear hybrids 
migrated fastest on the gel while the V-and Y-shaped RNA templates hybridized to their 
complementary RNA single strands (Figure 3.5A, lanes 4-9 and lanes 10-13, respectively) 
migrated slower on the gels. Long wave UV shadowing, Figure 3.5B revealed the FITC-labeled 
siRNA hybrids (Figure 3.5B, lanes 5-6, 8-9 and 11-13).  
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1    2    3     4      5     6    7     8     9    10  11 12   13   14 15 
  Linear                  V-Shape             Y-Shape 
1    2    3     4       5    6    7     8     9    10  11 12   13   14  15 
A B 
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Figure 3.4 Native PAGE of FITC-labeled siRNAs. Sequences in green represent FITC labeled 
sequences Lane 1: Dye; Lane 2 A1:S1; Lane 3 FL-A1:S1; Lane 4 V-78A194A1:78S194S1; Lane 
5 FL-V-78A194A1:78S194S1; Lane 6 V-78A194A1:78S1FL-94S1; Lane 7 V-
78A178A2:78S178S2; Lane 8 FL-V-78A178A2:78S178S2; Lane 9 V-78A178A2:FL-78S178S2; 
Lane 10: Y-78A194A175A1:78S194S175S1; Lane 11 Y-78A194A175A1:FL-78S194S175S1; 
Lane 12 Y-78A194A175A1:78S1FL-94S175S1; Lane 13 Y-78A194A175A1:FL-78S1FL-
94S175S1; Lane 15 Dye.  
 
Native PAGE of multi-FITC siRNA samples also confirmed successful hybridization, 
(Figure 3.4 A, B). In this assay, (Figure 3.6A) the lower molecular weight linear hybrids migrated 
fastest on the gel while the V-and Y-shaped RNA templates hybridized to their complementary 
RNA single strands which contained the FITC-label (Figure 3.4A, lanes 5-9 and lanes 10-13, 
respectively) were more retained on the gel. Long wave UV shadowing, Figure 3.5 B revealed the 
brilliant multi-FITC-labeled siRNA hybrids (Figure 3.5B, lanes, 7-8 and 11-13). 
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Figure 3.5 Native PAGE of multi-FITC-labeled siRNAs. Sequences in green represent FITC 
labeled sequences. Lane 1 Dye; Lane 2 empty; Lane 3 A1:S1; Lane 4 78A1:FL-78S1; Lane 5 
empty; Lane 6 V78A194A1:78S194S1; Lane 7 V-78A194A1:FL-78S194S1; Lane 8 V-
78A194A1:FL-78S1FL-94S1; Lane 9 empty; Lane 10 Y-78A194A175A1:78S194S175S1; Lane 
11 Y-78A194A175A1:78S194S1FL-75S1; Lane 12 Y-78A194A175A1:78S1FL-94S1FL-75S1; 
Lane 13 Y-78A194A175A1:FL-78S1FL-94S1FL-75S1; Lane 14 empty; Lane 15 Dye. 
  
 
3.4.4  Circular Dichroism (CD) Spectroscopy of siRNA Hybrids 
Circular dichroism (CD) spectroscopy was used to explore whether the siRNA hybrid 
structures maintained the prerequisite A-type helix geometry for RNAi applications.61  The linear 
siRNAs displayed typical CD profiles for A-form helices, with a minimum peak at 240 nm and a 
broad maximum in between 250-290 nm.62  In all cases, the FITC-linear, V- and Y-shaped template 
siRNA hybrids (Figure 3.6A), retained the A-type broad maximum and minimum bands were 
observed between 250-290 nm and 240 nm, respectively, albeit with a decrease in the amplitudes 
of the molar ellipticities at these characteristic wavelengths. The multi-FITC labeled siRNAs 
(Figure 3.6B), produced more pronounced deviations from the A-type RNA helix. In most cases, 
the maximum peak at 260 nm remained; however, with notable changes in molar elipticities at the 
characteristic maxima and minima within the 210-250 nm range. Taken altogether, the FITC-
 Linear           V-Shape             Y-Shape__ 
  3      4        5      6      7     8      9     10    11    12   13   14  
 Linear           V-Shape             Y-Shape___ 
3     4        5      6      7     8        9     10     11    12     13   14  
A B 
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labeled template siRNA hybrids were found to maintain A-type helices within their higher-ordered 
structure formulations while incorporation of multiple FITC probes within the siRNA hybrids was 
found to distort the A-type helix.  
 
  
Figure 3.6 Circular dichroism spectroscopy of (A) FITC-template siRNAs and (B) multi-FITC 
labeled siRNAs. All hybrid siRNA samples were prepared by annealing equimolar quantities (1.25 
nM) of antisense RNA templates with their complementary linear sequences. Samples were 
hybridized in annealing buffer (10 mM Tris, 50 mM NaCl, 1 mM EDTA, pH 7.5 – 8.0) by pre-
heating at 95 ºC (7 min) followed by slow cooling to room temperature over 1 h and overnight 
storage at 4 ºC prior to CD analyses. All samples were diluted in annealing buffer (1 mL) and the 
CD analysis was observed from 210-310 nm. 
-500000
0
500000
1000000
1500000
2000000
210 220 230 240 250 260 270 280 290 300 310
M
o
la
r 
E
lip
ti
c
it
y
Wavelength
78A1:78S1 Control
FL-78A1:78S1
FL-V-78A194A1:78S194S1
FL-V-78A178A2:78S178S2
Y-78A194A175A1:FL-
78S194S175S1
-1500000
-1000000
-500000
0
500000
1000000
1500000
2000000
2500000
210 220 230 240 250 260 270 280 290 300M
o
la
r 
E
li
p
ti
c
it
y
78A1:78S1
78A1:FL-78S1
V-78A194A1:78S194S1
V-78A194A1:FL-78S1FL-94S1
Y-78A194A175A1:FL-78S1FL-94S1FL-75S1
A 
 
 
 
 
 
 
 
 
B 
 
78 
 
3.4.5  Thermal Denaturation (Tm) analysis of siRNA Hybrids by UV-Spectroscopy 
SiRNA hybrid stabilities were measured by thermal denaturation (Tm) Figure 3.7 A-C. The 
addition of the FITC probe at the 5’ terminus of the antisense strand had little to no effect on hybrid 
stability. (Figure 3.7 B) For example, FITC-GRP78A1:S1 maintained similar hybrid stabilities 
(Tm: 63°C) to the native A1:S1 (Tm: 62°C).  Likewise, the FITC-V78A194A1:78S194S1 (Tm: 
5860 oC) and FITC-V78A178A2:78S178S2 (Tm: 5562°C) showed a very slight increase in 
thermal hybrid stabilities. The Y-shaped hybrids elicited a weaker hybrid stability, (Tm: 52 °C), 
however, like seen previously, incorporation of the FITC label had little to no effect on siRNA 
hybrid thermal stability. In the case of the multi-FITC siRNAs, the V-shape RNA template 
hybridized with two FITC-linear RNAs showed a slight increase in hybrid stability (Tm: 5865 
°C) while the Y-shape hybridized with three FITC-linear RNAs exhibited a significant increase in 
hybrid stability (Tm: 5268 °C). (Figure 3.7 C) Taken together, this data shows that attachment 
of the FITC probe into the template V- and Y-shape RNAs has little effect on the hybrid stability 
of the siRNAs, however, incorporation of multiple FITCs within a single siRNA construct shows 
enhanced stability of the siRNA duplex, which may improve their applications in biology. 
 
 
 
 
 
 
79 
 
 
 
  
Figure 3.7 Thermal denaturation, Tm, of non-labeled, (A), FITC-labeled siRNAs, (B), and multi-
FITC-labeled siRNAs, (C). All hybrid siRNA samples were prepared by annealing equimolar 
quantities (1.25 nM) of antisense RNA templates with their complementary linear sequences. 
Samples were hybridized in annealing buffer (10 mM Tris, 50 mM NaCl, 1 mM EDTA, pH 7.5 – 
8.0) by pre-heating at 95 ºC (7 min) followed by slow cooling to room temperature over 1 hr and 
overnight storage at 4 ºC prior to Tm analyses. Before running Tm, all samples were dissolved in 
annealing buffer (1 mL) and the Tm analyses were observed at 260 nm and plotted as observed 
changes in percentage hyperchromicity (%H) as a function of temperature, 20-80 ºC. 
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3.4.6  UV Absorption and Fluorescence Emission Spectra 
 Spectrofluorimetry was used to determine whether the siRNA hybrid structures had any 
effect on fluorescence intensity and quantum yields of the FITC probe. Previous studies on 
fluorescently labeled oligonucleotides have illustrated that covalent conjugation decreases 
fluorescence efficiency.48 FITC-siRNA hybrids (Figure 3.9) were prepared as described in the 
previous characterization studies. UV absorbance measurements were initially conducted to 
maintain absorption ranges of 0.1 – 0.01 (Figure 3.8) to limit inner filter effects that may be caused 
by more concentrated samples.63  
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Figure 3.8 UV absorption spectra of FITC-labeled template siRNAs (A) and multi-FITC siRNAs 
(B) 
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Figure 3.9 Multi-FITC siRNA samples pre dilution for fluorescence spectroscopy analysis. Linear 
78A1:FL-78S1 (A), V-78A194A1:FL-78S1FL-94S1 (B) and Y78A194A175A1:FL-78S1FL-
94S1FL-75S1 (C). 
 
Upon conjugation of FITC with the siRNA sequences, a blue shift (485 – 445 nm) was observed 
due to a variety of effects that can be contingent on temperature, environment and oligonucleotide 
length, sequence and conformation, which must be determined for each experiment.64 UV 
absorption studies revealed an overlap of the FITC-labeled siRNA samples, with an observed 
excitation peak selected at 460 nm. Upon excitation (λex: 460 nm), the emission spectrum was 
monitored (λem: 470-650 nm) for the FL-siRNA hybrids (Figure 3.10A). Interestingly, the linear 
FITC-78A1:S1 sample yielded comparable fluorescence emission intensity (ɸ = 1.3)   as the FITC 
fluorescent probe alone (ɸ = 0.93). Furthermore, a notable blue shift in the fluorescence emission 
maxima, λem: 515nm to 520nm was noted for the FL-siRNAs vs FITC alone. The V- (ɸ = 0.28, 
0.14) and Y-shaped (ɸ=0.15) FITC-labeled siRNAs displayed a significant quenching (70-85%) 
when compared to the linear FL-siRNA and the FITC control. The latter is presumably due to the 
nature of the extended sequence composition and higher-order structures of the V- and Y-shape 
siRNAs, which effects FITC fluorescence efficiency when compared to the linear FITC-labeled 
A     B     C 
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siRNA hybrid duplex. In order to overcome this limitation, multiple FITC-labeled complementary 
sense strand RNAs were hybridized to the template V and Y-shape RNA templates. The 
fluorescence emission spectra of the FITC-labeled V- and Y-shape siRNAs which incorporated 
two and three FITC fluorescent probes was found to increase fluorescence emission intensity by 
~5-fold (Figure 3.10B) although with still observable quenching effects (FL-S1 ɸ = 0.66, V-2FL-
S1 ɸ = 0.17, Y-3FL-S1 ɸ = 0.24) when compared with the siRNA with the incorporation of a 
single FITC probe (Figure 3.10A). The latter results underscore the potential utility of the self-
assembled higher-order V- and Y-shape siRNA motifs, facilitating the incorporation of multiple 
fluorescent probes for enhancing fluorescence detection and signaling for biological applications.  
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Figure 3.10 Fluorescence emission of (A) FITC-labeled siRNAs and (B) multi-FITC labeled 
siRNAs. All siRNA hybrids were prepared as previously described in annealing buffer (1.25 µM, 
10 mM Tris, 50 mM NaCl, 1 mM EDTA, pH 7.5 – 8.0, 1 mL). Absorbance readings were within 
the 0.1 – 0.01 range necessary for accurate fluorescence emission measurement. (A) UV 
absorbance of anti-sense FL-siRNA hybrids was conducted to determine the absorbance at the 
wavelength of excitation, 460 nm. Excitation of 460 nm and emission window of 470-650 nm. (B) 
UV absorbance of siRNA hybrids was conducted to determine the absorbance at the wavelength 
of excitation, 486 nm. Excitation of 486 nm and emission window of 490-610 nm.  
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3.4.7  Transfection and RT-PCR in PC3 Cells 
 The PC-3 prostate cancer cell line (ATCC® CRL-1435™) was used as a model, GRP 
overexpressing cell line to determine the knockdown efficiency of the FITC-labeled siRNA 
constructs.65 SiRNA transfections (10µM) were conducted with the TransIT-X2® Dynamic 
Delivery System transfection reagent within the PC-3 cell culture and incubated over a three-day 
(72h) period. RT-PCR of the isolated GRP mRNA sequences indicated that upon GRP78 mRNA 
knockdown a sharp upregulation of GRP94 was observed with a lower effect on GRP75 mRNA 
levels (Figure 3.11A). Presumably, this compensatory effect may be linked to the maintenance of 
the UPR under the stress-induced conditions, potentially linking the activity of these GRP 
chaperones.46 A similar trend was observed for the V-shaped siRNA targeting GRP78 and 94 
mRNA, with a noticeable upregulation of GRP75, albeit to a smaller extent. The Y-shaped siRNA 
targeting all three GRP chaperone proteins displayed the most synergistic mRNA knockdown (40-
70%). Analysis of the FITC-labeled siRNA constructs demonstrated GRP knockdown (20-70 %) 
albeit at a loss when compared to the non-FITC-labeled siRNAs (40-80 %). (Figure 3.11A) The 
decrease in GRP silencing activity of the FL-labeled siRNAs can be partially attributed to 
detrimental effects of functionalizing the 5’ terminus of the antisense siRNA strand which may 
inhibit incorporation into RISC and mRNA processing as part of the RNAi pathway.66 
Interestingly, when the sense strands were FITC-labeled and hybridized to the complementary Y-
shaped RNA template, the FITC-labeled Y-shape siRNA displayed comparable GRP knockdown 
efficiency (55-95%) as the non-FITC-labeled Y-shape siRNAs (40-80 %). (Figure 3.11B) The 
latter proves that RNAi activity can be restored within the higher-order V- and Y-shape siRNAs 
by FITC-labeling the complementary sense strands followed by siRNA hybridization into 
functional siRNA nanostructure formulations.67-69 
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Figure 3.11 qRT-PCR analysis of GRP75, 78 and 94 gene knockdown. 50nM siRNA samples 
were transfected into PC-3 cells and relative mRNA levels were normalized to a control siRNA. 
(A) Total mRNA levels were analyzed 72 h post transfection of the antisense FL-siRNA 
constructs. (B) Total mRNA levels were analyzed 48 h post transfection of the sense-strand FL-
siRNA constructs containing 1, 2 and 3 FITC probes (B).  
 
3.4.8  Internalization Efficiency via Flow Cytometry and Fluorescent Microscopy 
Incorporation of the FITC within the siRNA constructs provided the ability to monitor 
cellular uptake quickly and efficiently. PC-3 cells were treated with FL-siRNA and cell uptake 
measurements were determined by flow cytometry 3 h post transfection. Analysis of the linear, V- 
and Y-shaped FITC-labeled siRNA revealed a slight shift in fluorescence intensity vs the total 
gated cell population post transfection (Figure 3.13A). This data suggested that 3 hours may not 
be sufficient for complete siRNA uptake. To determine the optimal cell uptake time, a new set of 
siRNA samples were prepared (50 nM). PC-3 cells were transfected as previously described 
analyzed 20 hours post transfection by flow cytometry and revealed that FL-siRNA treatment at 
higher concentrations (100 nM) and treatment time (20 h) elicited the greatest shift in cell-based 
fluorescence intensity (Figure 3.12A). Interestingly, multiple incorporation of FITC upon 
A B 
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hybridization of complementary FL-sense strand RNA to V- and Y-shape RNA templates 
produced multi-FL probes which increased cell signaling in a time dependent (3-72 h) uptake 
experiment (Figure 3.12B). Fluorescent microscopy was used to validate internalization and 
verified the visualization of the FITC-siRNAs up to 24 h post transfection. (Figure 3.14) 
Therefore, the V- and Y-shape RNA templates efficiently enable the incorporation of multiple 
fluorescent probes for improving cell signaling and detection, while maintaining potent RNAi 
activity.   
  
  
Figure 3.12 Uptake efficiency monitored by flow cytometry of 50nM FL-siRNA transfection at 3 
and 20 h. (A) internalization efficiency of linear, V- and Y-shaped siRNA containing 1 FITC 
probe. (B) Time dependent internalization efficiency of linear, V- and Y-shaped siRNA containing 
1, 2 or 3 FITC probes, respectively.  
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Figure 3.13 Fluorescent microscope images of FL-siRNA transfected PC-3 cells at 4 and 24 hours 
post transfection. (A) FL-linear, (B) V-FL-siRNA containing 2 FITC probes, (C) Y-FL-siRNA 
containing 3 FITC probes 
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3.4.9  Western Blot 
 Following the qRT-PCR screening analysis of the FITC-siRNA samples, the lead Y-shaped 
siRNA containing three FITC probes was selected for further analysis. The Y-shaped siRNA 
sample (50nM) was prepared and transfected into PC-3 cells as described earlier. Cells were 
collected 72 h post transfection and subjected to qRT-PCR and western blot. RT-PCR showed 
mRNA knockdown of GRP78 (~40%), increased knockdown of GRP94 (~60%) and no visible 
knockdown of GRP75. However, western blot indicated protein level knockdown of GRP78 and 
75 (~30-35%) in both instances, but no visible knockdown of GRP94 at the protein level, which is 
known to vary from the mRNA transcript levels. 
 
Figure 3.14 Protein and mRNA knockdown levels of GRP75, 78 and 94 determined by Western 
Blot (A), and RT-PCR (B). *P< 0.05 in PC-3 cells and *P<0.01 in PC-3 cells. 
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3.4.10 Cell Viability 
Cell viability of the FITC-labeled siRNAs treated PC-3 cells was measured using 
propidium iodide (PI) staining. PI is a fluorescent intercalating agent that stains dead cells and is 
commonly used in flow cytometry to evaluate cell viability. PI cannot cross the membrane of live 
cells, making it useful to differentiate necrotic, apoptotic and healthy cells.70 PC-3 cell viability 
was determined at 24, 48 and 72 h post transfection to determine which construct exhibited the 
most potent cell death activity. (Figure 3.15 A, B) Following the 24 h incubation, it was noted that 
the supernatant contained PC-3 cells, as an initial indicator of cell death due to loss in adhesion. 
Both the supernatant cells as well as the cells still adhered to the bottom of the well were tested 
for viability. PI staining showed an increase in cell death over a 72h period for all samples. The 
Y-shape targeting all three GRPs elicited the most potent cell death in both cases.  
 
   
Figure 3.15 Cell viability determined using PI on flow cytometry, adhered cells (A) and 
supernatant cells (B) 
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3.5 Conclusions 
In the theranostic approach described in Chapter 3 of this thesis, the covalent attachment of a 
fluorophore, fluorescein isothiocyanate (FITC), has been developed for monitoring cell uptake, 
co-localization and biological activity within PC-3 prostate cancer cells. A wide range of GRP-
silencing siRNAs, including those adopting linear, V-shape and Y-branch structures allowed the 
incorporation of multiple FITC reporter probes. Although FITC-labeling had some effect on the 
requisite A-type helix structure required for RNAi activity, the fluorescent probe did not inhibit 
hybrid duplex stability according to thermal denaturation studies. Fluorescence quenching was 
observed in the higher-order V- and Y-shape siRNAs which enabled the incorporation of multiple 
FITC reporter probes, albeit with greater intensities of fluorescence emissions detected when 
compared to the siRNAs containing a single FITC. Upon transfection within the PC-3 prostate 
cancer cells, the FITC-labeled siRNAs triggered GRP mRNA and protein knockdown via RT-PCR 
and western blot, respectively, which resulted in loss of cell-based adhesion and cell death within 
the PC-3 cells. Flow cytometry and fluorescent microscopy also revealed the presence of the FITC-
labeled siRNA within PC-3 cells up to 72 hrs. Therefore, the V- and Y-shape multi-FITC labeled 
siRNA encompass a new class of theranostic agents with enhanced cell-based detection and RNAi 
activity in cancer.  
3.6 Experimental Section 
3.6.1 Materials and Methods.  
Chemical synthesis reagents and solvents were obtained from ChemGenes, Aldrich and 
VWR and used as received. Solid phase RNA synthesis reagents were obtained from ChemGenes 
or Glen Research Inc. and also used without further purification. Analytical thin-layer 
chromatography (TLC) was performed on aluminum-backed silica gel plates (Merck 60 F254). 
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TLCs were visualized under UV shadowing (260 nm) or staining (10% H2SO4/MeOH). Compound 
purification using silica gel chromatography was performed on 230-400 mesh silica (Sorbent 
Technologies). Molecular weights for the branchpoint uridine phosphoramidite was measured by 
direct injections on a Hewlett Packard series 1100 MSD equipped with ESI as ion-source in 
positive mode using 50/50 v/v MeOH/H2O at a flow-rate of 0.5 mL/min. Nuclear magnetic 
resonance spectra (1H, 13C, 31P COSY NMR) were recorded on a Varian NMR AS500 
spectrophotometer. NMR spectra were obtained at ambient temperature using an indirect pulse-
field gradient (ID-PFG) probe. The obtained data was processed using VNMRJ software (version 
2.2). Materials for cell biology were obtained from Thermofisher Scientific, Cell Signaling, 
Biolegend, Mirus and Invitrogen Life Technologies.  
3.6.2 FITC bioconjugation of linear, V- and Y-shape siRNAs  
 Linear, V- and Y-shaped siRNAs were selected to target the GRP chaperones (GRP-75, 78 
and 94) and the requisite RNA templates were synthesized as previously reported58 and 
summarized in chapter 2. Following synthesis, a 5’-DMS(O)-MT-Amino C6 modifier (Glen 
Research Inc.) was coupled to the 5’ terminal hydroxyl group using an extended 15-minute 
coupling time on an ABI 3400 DNA/RNA Synthesizer. The solid phase oligonucleotide synthesis 
cycle was continued with the coupling step (0.25 M ethylthiotetrazole in acetonitrile), capping 
(Cap A: 1:1:8 v/v/v acetic anhydride:pyridine:tetrahydrofuran, Cap B: 16% N-methyl imidazole 
in tetrahdrofuran) and oxidation (0.02 M iodine in 75:20:5 v/v/v tetrahydrofuran:pyridine:water) 
followed by removal of the DMS(O)MT protecting group with a detritylation step (3% solution of 
dichloroacetic acid in dichloromethane). The amino functionalized RNA templates were then 
subjected to a solid-phase bioconjugation reaction for the attachment of the fluorescent probe, 
fluorescein isothiocyanate (FITC). Following a previously reported method59 attachment of FITC 
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was achieved by reacting FITC (75 eq., 30 mg) dissolved in 20% aqueous N,N-dimethylformamide 
(DMF) in 0.1M carbonate-bicarbonate buffer (pH 8.5) to the deprotected amino modified RNA 
templates. The reaction was agitated at room temperature for 48 hours on a benchtop shaker. 
Following the reaction, the CPG bound RNA was washed with DMF and acetonitrile (MeCN) 
until no visible orange color remained in the supernatant. The sample was then cleaved and 
deprotected using 3:1 v/v NH4OH: EtOH at 55 ºC for 12-14 hours. The 2’-TBDMS protecting 
groups were desilylated using 1:1.5 v/v trimethylamine-trihydrofluoride TEA-3HF:DMSO at 65 
ºC for 2 h. The crude FL-RNA was precipitated in 3M NaOAc (25 µL) and n-BuOH (1 mL) and 
dissolved in diethyl pyrocarbonate (DEPC) treated Millipore water, RNase-free, for analysis and 
purification. 
3.6.3  RP IP HPLC  
The crude RNA templates were analyzed by Reverse Phase Ion Pairing High Performance 
Liquid Chromatography (RP-IP-HPLC) to determine crude purities. Briefly, HPLC analyses (0.1 
OD) and purifications (1 OD) were performed on a Waters® 2695 Alliance Separations Module. 
Crude RNA templates were dissolved in autoclaved water (1 mL) and injected into a Waters® 
SymmetryShield ™ RP-8 column (4.6 X 250 mm, 5µm particle size, 100Å) heated at 60 ºC. HPLC 
analyses and purifications were conducted using a gradient of 4-90% eluent B (50% acetonitrile 
in 0.1 M triethylammnonium acetate, TEAA) in eluent A (0.1 M TEAA). The HPLC flow rate was 
set at 1 mL/min, with run times of 25 min and with dual absorbance detection at 260 and 488 nm 
using a Waters® 2489 UV/Visible detector. Retention times (min.) and peak areas (% area) were 
integrated with Empower II software (Waters®) and used to confirm RNA purities ≥95% following 
sample purifications. 
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3.6.4  Mass Spectrometry 
  RNA templates (300-1300 pmol) were dissolved in RNase-free millipore water (50-200 
µL) and analyzed by Dr. Mark Hail at Novatia LLC, Newtown, PA. Samples were analyzed on an 
Oligo HTCS equipped ESI/MS in negative mode. The data was obtained and deconvoluted using 
ProMass software. Theoretical molecular weights were calculated by entering each sequence 
identity on IDT OligoAnalyzer. https://www.idtdna.com/calc/analyzer 
3.6.5  Denaturing Polyacrylamide Gel Electrophoresis 
 Purified template RNAs (300pmol) were loaded on a 24% denaturing PAGE (7M Urea) 
run at 300 V, 100 mA and 12 W for 3 hr. Following electrophoresis, the RNA bands were 
visualized under UV shadowing and stained with a Stains-All (Sigma-Aldrich™) solution. 
3.6.6  SiRNA Hybridization 
Purified complementary RNA strands were combined in equimolar quantities (200 pmol) 
and mixed in annealing buffer (35 µL, 10 mM Tris, 50 mM NaCl, 1 mM EDTA, pH 7.5–8.0) to 
afford the hybrid mixtures. The resulting mixtures were heated to 95ºC for 7 minutes on a heating 
block, slowly cooled to room temperature (22ºC) over 1 h and stored in the fridge overnight at 4ºC 
prior to analysis. 
3.6.7  Non-denaturing, Native Polyacrylamide Gel Electrophoresis (PAGE) 
The hybrid siRNA samples (10 µM) in annealing buffer (10 mM Tris, 50 mM NaCl, 1 mM 
EDTA, pH 7.5–8.0) were concentrated to minimal volume (~10 µL) and suspended in 30% sucrose 
loading buffer (15 μL in 1X TBE). Samples were loaded on a 16% native, non-denaturing PAGE 
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and run at 300 V, 100 mA and 12 W for 2.5 hr. Following electrophoresis, the siRNA bands were 
visualized under UV shadowing and stained with Stains-All (Sigma-Aldrich™) solution. 
3.6.8  Circular Dichroism (CD) Spectroscopy 
siRNA samples were hybridized in annealing buffer (1.25 µM, 10 mM Tris, 50 mM NaCl, 
1 mM EDTA, pH 7.5–8.0, 1 mL) as previously described. Samples were then transferred to fused 
quartz cells (1 cm path length) and incubated at RT under N2 for 2 minutes prior to spectral 
acquisition. CD spectra were collected on an Olis DSM 1000 Spectrophotometer as an average of 
3 scans with a 1.0 nm bandwidth interval and a 0.5 nm step interval. CD spectra were analyzed in 
between 210 and 310 nm, blank corrected with annealing buffer and smoothed prior to analyses. 
The raw data was exported into Microsoft Excel™ and plotted as changes in molar ellipticities (θ) 
with increasing wavelengths (210 – 310 nm). 
3.6.9  Thermal Denaturation (Tm) 
  All siRNA hybrids were prepared as previously described in annealing buffer (1.25 µM, 
10 mM Tris, 50 mM NaCl, 1 mM EDTA, pH 7.5 – 8.0, 1 mL). Thermal denaturation of the siRNA 
hybrids was performed using a CARY 3E, UV-Vis spectrophotometer, from 20 – 80 ºC, with 
temperature ramping of 0.5 ºC /min. The changes in absorption at 260 nm as a function of 
temperature was collected and the first derivative plot was used to determine the melting 
temperatures (Tm) of the siRNA samples. The data was transferred and plotted in Microsoft 
Excel™ as changes in the hyperchromicities (%H) observed at 260 nm as a function of temperature 
(20 – 80 ºC).  
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3.6.10  Fluorescence Emission and Quantum Yield (ɸ) Determination  
All siRNA hybrids were prepared as previously described in annealing buffer (1.25 µM, 
10 mM Tris, 50 mM NaCl, 1 mM EDTA, pH 7.5 – 8.0, 1 mL). UV absorbance measurements on 
a HP 8452A PDA spectrophotometer were initially conducted to determine FL-siRNA 
absorbances at the wavelengths of excitation, ex: 460 and em: 486 nm. Absorbance readings 
within the 0.1 – 0.01 A.U. range were recovered from serial dilution measurements necessary for 
accurate fluorescence emission measurements. Fluorescence emission and quantum yields were 
determined on a Horiba Fluorolog 3 spectrophotometer using FluorEssence V3.5 with an 
excitation of λex: 460 and emission window λem:  of 470-650 nm. Quantum yield values determined 
mathematically: (
𝐴𝑏𝑠 𝑜𝑓 𝐹𝐼𝑇𝐶
𝐴𝑏𝑠 𝑜𝑓 𝑆𝑎𝑚𝑝𝑙𝑒
) ∗ (
𝑀𝑎𝑥 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑆𝑎𝑚𝑝𝑙𝑒
𝑀𝑎𝑥 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝐹𝐼𝑇𝐶
) ∗ (0.93) 
3.6.11  Cell Culture  
 Prostate cancer cell line PC-3 (ATCC®) were cultured in RPMI 1640 complete growth 
medium supplemented with 10% (v/v) fetal bovine serum (FBS), and 1% (v/v) 
penicillin/streptomycin (P/S) under 5% CO2 at 37 ºC.  For passaging, PC-3 cells were detached 
with 0.25% trypsin and re-suspended with complete culture medium. 
3.6.12  SiRNA Transfections in PC-3 Cells and Cellular Uptake via Flow Cytometry and 
Fluorescence Microscopy 
 PC-3 prostate cancer cells (ATCC® CRL-1435™), 9.0 x104, were plated in 24-well culture 
plates containing RPMI complete culture media with 10% FBS. Cells were cultured in a 
humidified incubator set at 37 ºC with 5% CO2. Prior to transfections, the siRNA hybrids (7.5µL, 
10µM, in Opti-MEM, 133.5 µL) were mixed with the transfection reagent (TransIT-X2® Dynamic 
Delivery System, 9µL, in Opti-MEM, 250µL) according to the manufacture’s recommendation. 
99 
 
The mixtures were incubated (15 min, 22 ºC) then added to the PC-3 cell culture and incubated at 
37 ºC with 5% CO2 over a three-day (72 h) period. Samples were tested at 3 h and 20 h post-
transfection to determine internalization efficiency. Cells were removed from the well using 
trypsin and diluted in RPMI-1640 media. Samples were quantified using a Cytomics FC 500 flow 
cytometer. Time-dependent uptake for linear, V- and Y-shaped siRNAs containing one, two and 
three FITC probes was determined using CellInsight™ CX5 High Content Screening (HCS) 
Platform (ThermoFisher Scientific). Cells were visualized 2, 4, 8, 24, 48 and 72 hours post 
transfection. Images were analyzed using Thermo Scientific™ HCS Studio™ Cell Analysis 
Software. 
3.6.13 Gene Knockdown via Quantitative Real-Time Polymerase Chain Reaction (qRT-
PCR)  
Total RNA was isolated following transfections (48 h) from TriZol (Ambion) preserved cells using 
a TriRNA Pure Kit (Geneaid), following the manufacturer’s instructions. The collected RNA was 
then quantitated on a Qubit 3.0 fluorimeter using the Qubit Broad Range (BR) assay kit (Thermo 
Fisher Scientific). RNA (200 ng) was reversed transcribed into cDNA using a high capacity cDNA 
kit (Applied Biosystems). RT-PCR was performed using pre-developed TaqMan™ gene 
expression primer-probes for GRP78 (assay ID Hs99999174_m1), GRP94 (assay ID 
Hs00437665_g1), GRP75 (Hs00269818_m1), and GAPDH (Hs99999905_m1) and 
TaqMan™ fast advanced master mix. qPCR fast assay was carried out on a StepOnePlus (Applied 
Biosystems). Fold changes were calculated with the ΔΔCt method using GAPDH as endogenous 
control and the negative siRNA as the control sample. 
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3.6.14 Western Blot 
 Total protein was isolated from the cell cultures following transfection (78 h). Protein 
lysates were prepared by lysing the cells in ice-cold RIPA buffer (G-Biosciences) supplemented 
with protease and phosphatase inhibitors (Millipore Sigma) which were diluted 1:10 as per the 
manufacturer’s recommendations. Cell debris was removed by centrifugation at 16,000g at 4°C 
and protein concentrations were determined using a PierceTM BCA kit (Thermo Fisher Scientific). 
A sample (20-35 mg) of the supernatant protein was mixed with LDS buffer and DTT, incubated 
at 70 °C for 10 min and resolved on a 4-12% Bis-Tris PAGE gradient gel before being transferred 
to a PVDF membrane. Following transfer, the membrane was blocked in 5% skim milk for 1 h, 
washed and incubated at 4 °C overnight with a rabbit 1° mAb against human GRP78, GRP94, 
GRP75 or GAPDH (all purchased from Cell Signaling Technology) at a 1:1000 dilution. The 
membrane was subsequently washed and incubated with an anti-rabbit HRP-conjugated 2° Ab 
(Cell Signaling Technology) for 1 h at room temperature at 1:2000 dilution. The bands were 
visualized using a SignalFire™ ECL reagent (Cell signaling Technology) on a ProteinSimple 
FluorChem E imager. 
3.6.15 Cell Viability  
Cell viability was determined in 24-well plates with PC-3 cells cultured in RPMI complete growth 
media and then incubated in the presence or absence of FITC-siRNA (50 M) for 72 h at 37 o C. 
After 24, 48 and 72 hrs, the supernatant was collected and the remaining cells were removed using 
trypsin. Cell samples were pelleted and re-suspended in 1% BSA in PBS (1 mL) and stained using 
PI (100 µL) according the manufacturer’s recommendation. Samples were quantified using a 
Cytomics FC 500 flow cytometer (Beckman Coulter). Data was processed with 
Kaluza® (Beckman Coulter) flow analysis software.  
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CHAPTER 4: CONCLUSIONS AND CONTRIBUTIONS TO KNOWLEDGE 
4.1 Conclusions and Contributions to Knowledge made in this Thesis 
4.1.1 Development of Higher-Order siRNA hybrids for RNAi Mediated Cancer Gene 
Therapy 
 
 With the rapid expansion and advances that have been made in the field of RNA 
nanotechnology, the ability to design single siRNA nanostructures that can deliver multiple 
siRNAs presents an intriguing opportunity for screening of a wide range of oncogene targets while 
potentiating cancer gene therapy effects. Chapter 2 described the optimization of the synthesis 
strategy of a branchpoint amidite, for the incorporation within the solid phase synthesis of novel 
V- and Y-shaped RNAs. The solution-phase synthesis of the requisite branchpoint amidite, 5’-
O-levulinyl (Lv) 2’-O- monomethyoxytrityl (MMT) ribouridine phosphoramidite was based on 
an optimized 3-step synthesis strategy featuring: (a) synthesis of levulinic anhydride followed 
by chemo-enzymatic levulination of the 5’ ribouridine hydroxyl group using lipase acrylic resin 
from Candida antarctica; (b) tritylation of the 2’ hydroxyl group and (c) phosphitylation of the 
remaining 3’ hydroxyl group (Scheme 2.1). The branchpoint amidite was used to develop a 
library (26) of siRNAs designed to target multiple GRP chaperone proteins and elicit a more 
potent, synergistic knockdown and cell death effect. The siRNAs were synthesized in good crude 
yields (≥62%) and purified using IP-RP-HPLC to obtained sequence purities (≥97%) whose 
identities were confirmed by ESI-MS (Table 2.1). 
 The RNA templates were hybridized with their complementary sequences in Tris annealing 
buffer using stoichiometric ratios that promoted self-assembly. A native PAGE was used to 
confirm hybridization and self-assembly into higher-order structures, (Figure 2.2). CD and 
thermal denaturation studies showed retention of the A-type helical geometries (Figure 2.3 A, B), 
as well as high thermal stability (Figure 2.4 A, B) which are crucial for RNAi activity. 
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The lead siRNAs produced the most pronounced GRP78 knockdown and apoptosis of the 
AN3CA cancer cells. Furthermore, this study also revealed the influence of multiple GRPs (GRP-
75, 78 and 94) on MDA-MB-231 (breast cancer), HeLa (cervical cancer), AN3CA (endometrial 
cancer) and MRC5 (non-tumorigenic lung cells) cells’ survival. The Y-shaped siRNA targeting 
multi-chaperones (GRP-75, 78 and 94) revealed synergistic effects of silencing the GRP chaperone 
in cancer (Figure 2.5 A, B). More specifically, cancer cells were found to be more susceptible to 
siRNA silencing relative to the control, non-cancerous cells (Figure 2.5 C). Therefore, the self-
assembled siRNA hybrids targeting multiple GRPs may provide specific and more potent 
anticancer activities. These findings are not only important for enhancing the gene therapy effects 
of siRNAs but also for screening the influence of oncogene targets on the progression of cancer.   
4.1.2 Fluorescently Labeled siRNAs and their Theranostic Applications in Cancer Gene 
Therapy 
Gene therapy has re-emerged as a promising precision nano-medicine strategy in the 
targeted detection and therapy of cancer. The integration of therapy and diagnostics “theranostics” 
have gained significant traction in the development of new and improved gene therapeutics that 
effectively diagnose and treat cancers at the onset of the disease. Building on the work described 
in Chapter 2, Chapter 3 of this thesis reports a theranostic application in which a fluorophore, 
fluorescein isothiocyanate (FITC), was covalently attached to the siRNAs to produce a library of 
higher-order FITC-labeled siRNAs. These newly synthesized FITC-siRNAs provide the unique 
opportunity to track mechanism of action by monitoring cell uptake, co-localization and biological 
activity of a wide range of GRP-silencing siRNAs, including those adopting linear, V-shape and 
Y-branch nanostructures. The linear and V- shaped FITC-siRNAs were synthesized in moderate 
yields (~20%) and purified using IP-RP-HPLC to obtained sequence purities (≥95%) with 
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identities were confirmed by ESI-MS, (Table 3.1). The Y- shaped FITC-siRNA was not 
successfully synthesized using our solid-phase bioconjugation approach. In order to overcome this 
limitation, the Y-shape RNA template was hybridized with complementary sense RNA strands 
which contained the FITC label. This self-assembly procedure was also adopted with the V-shape 
RNA template, and provided the opportunity for the incorporation of multiple FITC probes within 
single molecular, RNA nanostructures. 
A native PAGE was used to confirm hybridization of the FITC-siRNA sequences, (Figure 
3.5 and 3.6). Moreover, CD and thermal denaturation studies revealed A-type helical geometries 
(Figure 3.7A) as well as similar hybrid stability (Figure 3.8B), of the FITC-siRNA constructs 
when compared to their non-labeled counterparts (Figure 3.8A). Fluorescence spectroscopy 
showed that upon conjugation with the linear and V- shaped siRNAs the fluorescence intensities 
was quenched, (Figure 3.10A) In an effort to overcome the quenching effects, the non-labeled 
linear, V- and Y- shaped templates were hybridized with their complementary FITC-linear stands 
to afford siRNAs containing multiple FITCs within a single construct. Incorporation of the 
multiple FITCs did not overcome the quenching effect, (Figure 3.10B); however, increases in the 
fluorescence emission intensities were observed for these multi-FITC labeled siRNAs.  
Silencing efficiency of the FITC-labeled siRNAs within a prostate cancer cell line (PC-3, 
ATCC® CRL-1435™) was determined via RT-PCR and western blot. In all cases, FITC-siRNA 
hybrids (50nM) exhibited less mRNA knockdown (~10-30%) when compared to their non-labeled 
counterparts (~40-80%), (Figure 3.11A). Incorporation of the FITC probe onto the sense strand 
of the siRNAs regains mRNA knockdown (~50-<90%), (Figure 3.11B) which also translates to 
more potent cell death over a 72 h period (~20-95%), (Figure 3.15 A, B). Uptake efficiency of the 
multi FITC-siRNAs, monitored via flow cytometry, revealed the most cellular uptake within 2-4 
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h, (Figure 3.12 A, B). However, the multi FITC-labeled siRNA maintains strong fluorescence, 
(Figure 3.13) even up to 72 hours post-transfection as discerned by flow cytometry, (Figure 3.12 
B). The lead Y-shaped siRNA, was selected to validate the effects of GRP knockdown on cell 
viability. Western blot revealed slight knockdown of GRP75 and 78 at the protein levels (Figure 
3.14 A), whereas RT-PCR showed mRNA knockdown of GRP78 and 94 (Figure 3.14 B). Taken 
together, the data presented within this thesis outlines the unique potential for these novel 
multifunctional siRNA nanostructures to behave as potent theranostics for cancer gene therapy. 
4.2 Future Work 
 While the data presented within this thesis is self-sufficient, further work can be 
accomplished by improving the theranostic capability of these FL-siRNAs. This thesis describes 
the incorporation of a single fluorophore, FITC; other fluorophores (e.g. Cy3/5) can be used to 
extend the dynamic range of detection into the red or near-IR regions of the electromagnetic 
spectrum. Incorporation of additional fluorophores would enable multiple wavelengths of 
detection, which would allow for in depth mechanistic studies related to uptake, co-localization 
and RNAi activity of the novel V- and Y-shape siRNAs. The incorporation of FRET probes (e.g. 
Cy3/5) within these FL-siRNAs could also allow for enhanced mechanism of action studies, 
including new insights on structure dynamics related to siRNA processing during the RNAi 
mechanism. For example, in the hybrid form, the siRNA labeled with the FRET pair would quench 
the fluorescent signal, however, upon incorporation into RISC, the FL-siRNAs would denature 
and separate the FRET pair enabling fluorescence emission. This would allow for accurate 
determination of the kinetics involved in siRNA incorporation within RISC for processing activity. 
Additionally, our solid phase RNA synthesis strategy allows for the incorporation of modified 
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nucleic acids (e.g. 2’OMe and 2’F RNA) which would enhance siRNA stability and improve 
silencing activity. 
 Moreover, siRNA delivery is another important aspect of our proposed future work. A 
transfection agent applicable for in-vitro assays is not easily translated in vivo or within clinical 
applications. Therefore, we envisage combining the FL-siRNAs with a cancer targeting or cell 
penetrating peptides to improve internalization specificity and efficacy of the FL-siRNA 
nanostructures in cell lines and within in vivo xenograft tumor models. The latter can be used to 
develop a cancer-targeting gene therapy approach to selectively silence oncogene activity within 
tumors while leaving healthy ones unscathed. We anticipate the development of novel precision 
medicine approaches to address many of the shortcomings associated with non-selective forms of 
cancer therapy. In this manner, our biological probes may be effectively translated from pre-
clinical to clinical utility. 
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